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 The Surgeon General recently issued a call to action to reduce the incidents of 
blood clots, which can cause pulmonary embolism, deep vein thrombosis, and stroke. 
This research study was conducted to assess what risk information is available to women 
regarding thrombosis (blood clots) and thrombophilia (clotting disorders) in combination 
with birth control pills, what women know about this issue, and how to increase this 
awareness.  A media analysis showed that very little information is available to women 
about thrombosis and thrombophilia with regard to birth control pills. It also 
demonstrated that the information that is available is often inadequate or inaccurate.  
 The survey of women who have taken or are taking birth control pills showed a 
lack of awareness of the side effects of birth control pills, thrombophilia, thrombosis, or 
the symptoms of thrombosis. Most women taking this medication that increases their risk 
of blood clots are not even aware of the symptoms of blood clots. Additionally, only one 
woman out of 311 could correctly identify all of the health risks associated with birth 
control pills. The survey results also showed that the majority of women would not only 
be willing to take a blood test to determine if they have thrombophilia, but more than half 
would be willing to pay for it.  
 In order to reduce thrombosis, awareness of these conditions can be increased by 
pharmaceutical manufacturers taking a greater responsibility for producing easily 
understandable risk information. Also, health care providers and patients must 
communicate more effectively. At a minimum, testing should be offered to women, if not 
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The educated differ from the uneducated as much  
as the living from the dead. 
-Aristotle 
MY STORY 
I opened my eyes and saw my husband, Josh, leaning over me. I was on my side 
in the emergency room and the doctor had just asked Josh to hold me steady while he 
gave me a spinal tap to check for meningitis.  Josh held me so firmly, understanding the 
consequences of a misplaced needle, that his arms were shaking from the strain. The 
doctor attempted a lighthearted joke about me getting an epidural in the future and Josh 
laughed nervously. I wanted to tell him, “Don’t worry about holding me steady. I can’t 
move anyway.” I had lost the use of my limbs hours before, maybe even days. And now 
it seemed my power of speech was gone, as well.    
 It was not the first time Josh had to hold me down. Earlier that day, he had tried to  
restrain me while my body thrashed wildly, nearly bucking him off the couch.  During 
the seizure, I told myself that if I just calmed down, it would stop. It must be all in my 
head, since I had already been sent home from the emergency room twice in as many 
days. When the shaking finally subsided, we locked eyes, both of us terrified of what was 
happening to me. Josh asked me if he should call 911 again. All I could do was nod. 
 I did not have meningitis. I had a common blood condition that predisposed me to 
getting blood clots. And when combined with the estrogen in my birth control pills- pills 
that I had been taking for ten years- this common condition was nearly fatal. The blood 
clots were in my brain, and because they had not been treated right away, one of the veins 






On September 15, 2008, the Office of the Surgeon General issued a Call to Action 
to reduce the number of cases of venous thromboembolism (VTE), including deep vein 
thrombosis (DVT) and pulmonary embolism (PE), in the United States. Together, these 
conditions affect an estimated 350,000 to 600,000 Americans each year, causing at least 
100,000 fatalities. Acting Surgeon General Steven K. Galson, M.D., M.P.H. said, “It’s a 
silent killer. It’s hard to diagnose. I don’t think most people understand that this is a 
serious medical problem or what can be done to prevent it.” He urged all Americans to 
learn about and prevent these treatable conditions.  
“It is well established that thrombosis is a complex disease with a very high 
genetic component (i.e., heritability of 61%) that determines the risk of disease” (Lopez 
et al. 349). Researchers have found that VTEs develop most frequently in people who 
have both genetic risk factors and circumstantial increased risk factors. Circumstantial 
factors that increase the risk of thrombosis include age, inactivity, surgery, pregnancy, 
oral contraceptives, hormone replacement therapy, and obesity. Genetic risk factors 
include inherited thrombophilias. “Thrombophilia may… be defined as both an acquired 
or congenital abnormality of haemostasis predisposing to thrombosis” (Middeldrop 1). 
Or, in more common terms, thrombophilia is a blood condition that increases the 







FACTOR V LEIDEN 
“In the 1990’s, several gene mutations were found to substantially increase the 
risk of thrombosis” (Mohllajee 166). One of these is factor V Leiden (FVL), a 20,000-
year-old mutation common in the general population and a major genetic risk factor for 
thrombosis (Dahlback 19). The prevalence of factor V Leiden varies among different 
ethnicities and is highest in Caucasians but significantly lower in other groups (Eckman 
et al. 109). This genetic mutation is found in approximately 3-7% of the Caucasian 
population (Walker 8). Factor V Leiden can present in patients as either heterozygous, 
when the patient has inherited one mutated gene from a parent, or homozygous, where 
the patient has inherited two mutated genes, one from each parent (Crawford 26). 
 “The factor V Leiden mutation appears to increase the risk of VTE 
approximately 7-10 fold and in Caucasians is at least 10 times more prevalent than any of 
the natural anticoagulant deficiencies” (Walker 9). It is the most common genetic cause 
of primary and recurrent venous thromboembolism in women (Ament 51).  
One circumstantial factor that can increase the risk of blood clots, stroke, and 
heart attack in women is taking estrogen. When someone with FVL takes estrogen, her 
risk of blood clots increases exponentially. Whether women are taking estrogen in the 
form of oral contraceptives, have increased levels of estrogen due to pregnancy, or are on 
hormone replacement therapy, they are at much greater risk of clotting. Lidegaard, et al. 
found that the “risk [of VTE] increased more than 100% with increasing estrogen dose” 
(187). Mohllajee et al. found 10 studies that provided evidence of a greater risk of VTE 
among oral contraceptive users with FVL. According to Dahlback in his review of blood 




Hematology, women with heterozygous FVL who also use oral contraceptives have an 
estimated 30 to 50-fold increased risk of blood clots, while women with homozygous 
FVL have a several hundred-fold increased risk (24).  
Additionally, FVL accounts for 20-50% of the venous thrombosis events that are 
pregnancy related (Ament 51). And in the United States, VTE is the leading cause of 
maternal death (Dresang 1709). In addition to causing VTE in pregnant women, FVL has 
been linked to miscarriage, preeclampsia, placental abruption, and stillbirth. “In a recent 
review, 25 studies were evaluated investigating the association between thrombophilia 
and early pregnancy loss (first and second trimester) and 15 studies were analyzed to 
define the association between thrombophilia and late pregnancy loss (third trimester). 
Significant associations with early and late pregnancy loss were observed for carriers of 
heterozygous factor V Leiden mutation… associations in late pregnancy loss are even 
stronger than in first trimester miscarriages” (Lindhoff-Last 24).  
Perhaps the women most at risk for blood clots are those that have been placed on 
hormone replacement therapy (HRT). A recent review of data from eight observational 
studies and nine randomized controlled trials found that women taking the oral form of 
the drug were two to three times more likely to develop a blood clot (Oral HRT increases 
risk of blood clots 7). And women with factor V Leiden who are also on HRT were 14-16 
times more likely to have a VTE  (Park 463). 
Despite these risks, women are not systematically tested for FVL before they are 
prescribed oral contraceptives, before or during pregnancy, or before commencing HRT. 
This is due to a series of outdated cost-effectiveness studies that found the benefits, 




Regardless of the cost of the tests, women are not even informed about these inherited 
and dangerous conditions.  
 
COMMUNICATION 
The problem with not informing women of the dangers of clotting disorders when 
taking birth control pills becomes even more apparent when the number of women taking 
them is considered. According to the National Center for Health Statistics, it is estimated 
that 11.8 million women in the United States, and 80 to 90 million worldwide, use oral 
contraception. And recent studies have suggested that 80% of women around the world 
use oral contraceptives at some point between the ages of 18 and 24 (Berry, et al. 305). 
As Berry, et al. point out, “Given the widespread usage, one might expect people to have 
a good understanding of the risks involved” with taking oral contraceptives, “however, 
recent research has shown that even relatively well educated women were woefully 
uneducated about the side effects” (305).   
Bryden concurs adding that “there are many misconceptions about both the 
health-related benefits and health-related risks of [oral contraceptive] use” and that 
younger women appear to be even less knowledgeable (223). In their 2001 study, 
Fletcher, et al. found that procedures surrounding the prescription of oral contraceptives 
are inconsistent among health care professionals (231).  Their study also indicated that 
women lack adequate knowledge about pill use (233).   
A study done by Tatum et al. in Mexico City found that “both public and private 
physicians asked few questions and provided little information regarding screening, pill-




Unfortunately no similar studies could be found for physicians in the United States, 
though the findings presented in this thesis are comparable.  
In 2002, the Berry et al. study tested the effectiveness of the warning information 
provided to women taking the pill. They found “that less than 12% of educated women 
fully understood the absolute levels of risk of thrombosis from taking the pill” and that 
“understanding of relative risk was also poor, with less than 40% showing a full 
understanding and 20% no understanding” (Berry 306). And “recent research has shown 
that even highly educated people have difficulty comprehending abstract quantitative 
information, such as statistics about the chance of experiencing complications from 
treatment” (Zikmund-Fisher 113).  
Additionally, a recent study by Gigerenzer et al. has shown “that information 
pamphlets, Web sites, leaflets distributed to doctors by the pharmaceutical industry, and 
even medical journals often report evidence in nontransparent forms that suggest big 
benefits of featured interventions and small harms” (53). According to their research, the 
majority of the sources that doctors use for information are incomprehensible to them, or 
worse, give them a false understanding of treatment benefits and risks.  
If women and even their doctors do not understand the risks associated with birth 
control pills, it is unlikely that they will further have knowledge of clotting disorders and 
how they increase these risks. To this, a study by Hellman et al. of patients with FVL 
found that “fewer than half the individuals (47%) felt comfortable with their healthcare 
providers’ understanding of FV Leiden.” They also found that 42% of the patients 
surveyed tried to research FVL independently without much success. The study indicates 




Indeed, it would be highly unusual for a woman to come across information about 
factor V Leiden or any other, less common clotting disorder. If one were to search the 
term “factor V Leiden” in any of the major search engines (Google, Yahoo, AOL, MSN- 
searched on March 23, 2009) the main site that is found is www.fvleiden.org.  This site 
describes itself as the “Thrombophilia Awareness Project” and “the web’s resource for 
patient based thrombophilia information.” It was created in 1998 by Debra Okner Smith, 
a woman with factor V Leiden who wanted to provide a resource for other people with 
the clotting disorders. Smith has since obtained the input of Dr. Stephen Moll, director of 
the Thrombophilia Program at the University of North Carolina, Chapel Hill to answer 
questions on one page of the website. Regardless of the modest input by Dr. Moll, the 
main online resource for factor V Leiden was started and is maintained by a woman with 
no medical background, aside from her own personal history of clotting disorders 
(including a DVT while she was on oral contraceptives). 
The National Alliance for Thrombosis and Thrombophilia (NATT) maintains the 
website www.stoptheclot.org, an excellent resource for information on blood clots and 
clotting disorders. However, this site does not appear on the first page of any of the 
previously mentioned search engines for any of the following keywords: factor V Leiden, 
blood clots, clotting disorders, or thrombophilia. How can a resource help if it cannot be 
located? 
For as common as factor V Leiden is in the general population, it receives very 
little attention, especially in the United States. To better understand the level that factor V 
Leiden is discussed, I signed up for a Google alert, an email from Google each week 




any Internet activity that Google found with the term “factor V Leiden.” Fewer than a 
dozen news stories were located, with most of those originating in India. The majority of 
the links included in the Google alerts were to blogs kept by women who were having 
fertility issues. Many of these women had miscarried two or three times or suffered 
stillbirths before being tested and found positive for factor V Leiden.  One blogger shares 
(Radical Catholic Mom): 
Factor V Leiden is one of the things I *SHOULD* have been tested for when I lost 
our first second trimester baby and I had to fight to get tested for for[sic] our second, 
second trimester loss. It is a simple blood test. I have no clue why they won’t test for 
it. 
 
If the warning information that comes with birth control pills does not adequately 
inform, even educated women; and if information on blood clots and clotting disorders is 
difficult to find; and if many doctors do not even inform patients of the risks of taking 
birth control pills or thrombophilia; what information is available to women about blood 
clots and thrombophilia, what do they actually know, and how can this knowledge be 
increased? This research attempts to answer these questions by analyzing information 
that is available to women and what information may be lacking.  Women who have 
taken birth control pills were then surveyed to assess what information they already know 
and determine any deficiencies in their understanding. Finally, results of the first two 










The aim of this study is to assess the understanding women have about blood clots 
and clotting disorders, and offer methods of increasing this awareness. Though all women 
with increased estrogen levels, whether through pregnancy, oral contraceptive use, or 
hormone replacement therapy, are at a higher risk of blood clots; for the purposes of this 
study, I focused primarily on awareness in women who have taken or are taking oral 
contraception. If 80% of women use oral contraceptives as young adults, increasing 
awareness when they are given the prescription could help prevent clots not only during 
the use of the medication, but also in future risk situations. Awareness in younger women 
could mean fewer clots in women during pregnancy and menopause, when hormone 
replacement therapy is generally prescribed. And possibly fewer blood clots caused by 
long flights, surgeries, and other circumstantial situations.   
To determine how best to increase awareness of thrombophilia and the symptoms 
of blood clots, I first had to research what information is currently available to women 
and what women actually know about the subject. Therefore this study has three parts: 
I. What information is available about the health risks, symptoms of blood clots, and 
clotting disorders with regards to oral contraceptives? 
 
II. What do women understand about the health risks, symptoms of blood clots, and 
clotting disorders with regard to oral contraceptives? 
 
III. How can women’s understanding of health risks, symptoms of blood clots, and 
clotting disorders be improved? 
 
To address my first question, I reviewed what information was available to 
women by analyzing three samples from each of three types of informative media. These 




information, and inserts from pharmaceutical companies that are included in birth control 
pill packaging. Each media was chosen for the specific reasons outlined below. 
Advertisements were the first medium chosen for analysis. Being exposed to 
advertisements is a passive process and analyzing print advertisements allowed me to 
review what kind of information women are exposed to when they are not seeking out 
information about birth control pills. Since 1997, when the FDA modified their 
regulations regarding pharmaceutical advertising, manufacturers have greatly increased 
their efforts to market direct to consumers and have increased their spending on 
advertising from $40 million in 1997 to $4.4 billion in 2004, an increase of over 10,000 
percent (Choi 137). According to a survey conducted by the Food and Drug 
Administration (FDA) in 2002, 81% of participants reported that in the past three months 
they had seen or heard a prescription drug advertisement. That same year, 92% of 
physicians surveyed reported that they had patient-initiated discussions about advertised 
drugs. (Kaphingst 516).  
Print advertisements were chosen over advertisements in other media because 
they contain more risk information. This is partly due to space and partly due to a 
provision by the FDA allowing drug companies that are advertising on television to refer 
consumers to concurrent print advertisements for additional information about drug risk 
and side effects (Kaphingst et al. 516). And in 2006, the FDA found the most common 
violation in pharmaceutical advertising was inadequate risk information. 
The second medium analyzed was websites. Compared to print advertisements, 
web usage is a much more active process of obtaining information and is continually 




American Life Project showed that 79% of those surveyed had searched for health 
information online, which translates to approximately 95 million Americans. 
Furthermore, those most likely to search for health information online were women 
younger than 65. (Rice 9-10). In a 2007 study, Warner and Procaccino found that women 
who use the Internet are most active at seeking health information (801).  
The three websites selected were health sites containing information about birth 
control pills. These sites were selected by inputting the keyword “birth control pills” into 
four search engines, with the results cross-referenced for the most popular results. 
Coincidentally, all three sites were maintained by not-for-profit organizations. 
The third medium examined in this study was the inserts created by 
pharmaceutical companies that are included with packets of birth control pills. These 
inserts could be considered active or passive types of information depending upon how 
each consumer utilizes them: passive because a woman has simply to obtain birth control 
pills to receive the information; active because women would have to actually read 
through a great deal of dense material printed in very small font in order to glean any of 
the information provided.  
Additionally, the pharmaceutical inserts are technical documents and were 
analyzed accordingly. One of the central tenets of technical communication is to consider 
your audience and design accordingly. As Schriver points out in Dynamics in Document 
Design, “Since people rely on documents to make decisions that influence their safety, 
livelihood, health, and education, the highest ethical standards must be brought to bear in 




what pharmaceutical inserts include and exclude, is of the utmost importance; as is how 
that information is presented. 
Each item was reviewed for content and information about risk and side effects. 
Specifically, each item was examined for information to answer the following: 
• Did the information state that thromboembolism is a health risk? 
• If so, did the information state that genetic disorders can increase the risk of 
thromboembolism? 
 
• Did the information list symptoms of a thromboembolic event? 
• Did the information tell women with symptoms of thrombolic event what to do in 
that situation (i.e. got to the emergency room, etc.)? 
 
In addition to these questions, the media were given a general overview with 
respect to how content and design conveys information. The choice of language was also 
analyzed, as wording plays an important role in our understanding of risk and benefit. As 
Davis has found, “the presence of qualifying language actually increases consumers’ 
positive perceptions of the drug and reduces the estimates of how likely they would be to 
encounter specific side effects” (620). Qualifying language often includes conditional 
words like ‘may’ and ‘could.’ For example, research has shown that phrases like ‘some 
side effects may occur’ or ‘this medicine could cause certain side effects’ have a 
“profound effect on the likelihood [of a patient to] request a drug and the anticipated 
positive experience of using a drug” (Davis 619). 
To address the second part of my research question, I surveyed women who have 
taken or are taking oral contraception. The survey was created using SurveyMonkey.com 
and contained a variety of question types including multiple choice, fill in the blank, and 




requirements that the participant had to be over 18 years of age and have taken birth 
control pills. The link to the online survey was emailed to friends and colleagues with the 
request that they forward it to any woman that met the criteria and would be willing to 
participate. Additionally, the link to the survey was posted on the social networking 
website Facebook.com.  
Women were first questioned about their experience with birth control pills 
including interactions with both their healthcare provider and pharmacist. Then, the 
participants were asked about their knowledge of the risks involved with taking birth 
control pills, their behavior concerning prescription warning information, and where they 
are most likely to seek medical information. Finally, they were asked about 
thrombophilia, symptoms of blood clots, and whether they would be willing to take a 
blood test to assess their risk of blood clots.  
The survey remained active online for 10 days during which time more than 300 
responses were collected. After which the survey was deactivated and the results were 
collected from SurveyMonkey.com. The survey responses were then reviewed and 
analyzed. Questions that had “Other (please explain)” as an option were coded to see if 
the responses could be categorized into one of the other selections. After coding, the 
results were modified to reflect the updated responses. 
The research collected through the media analysis and the survey was then 
reviewed to determine what information is lacking and how that information can be better 








To understand how risks are communicated to women with respect to 
thromboembolisms and birth control pills, this study analyzed magazine advertisements, 
websites, and the actual materials from pharmaceutical companies that accompany the 
OCs. For each medium, the information was examined for the following criteria: 
• Did the information state that thromboembolism is a health risk? 
• If so, did the information state that genetic disorders can increase the risk of 
thromboembolism? 
 
• Did the information list symptoms of a thromboembolic event? 
• Did the information tell women with symptoms of thrombolic event what to do in 
that situation (i.e. got to the emergency room, etc.)? 
 
In addition to these questions, each item was reviewed for design and word 
choice. The choice of language was also analyzed for how it affected the risk 
communication, especially with regards to qualifying language.  
 
ADVERTISEMENTS 
Advertisements for birth control pills can be a major factor in sales, as evidenced 
by Yaz, which saw an increase in sales from $262 million in 2007 to $616 million in 
2008, after an extensive advertisement campaign (Singer). Clearly advertising, at least for 
birth control pills, remains an effective means of marketing and persuasion.  For this 
study, three print advertisements for birth control pills were selected for examination, two 
from popular women’s magazines and a third that was distributed at a student health 





The first advertisement was for Yaz, the self-proclaimed “#1 brand birth control 
pill” and according to the New York Times, the best-selling oral contraception pill in the 
United States. The advertisement was taken from the December 2008 issue of Shape 
magazine, a popular women’s magazine with a fitness focus. This advertisement is 
comprised of three magazine pages (back of one page, and front and back of a second 



















The top three quarters of the first page of the Yaz ad (Figure 3.1) is a picture of a 
smiling woman with her arms in the air. Balloons with terms like “acne” and “irritability” 
float high above her head. The visual rhetoric of the advertisement indicates that the 
woman is no longer tethered to “acne” and “irritability” and therefore carefree and happy.  
Under the carefree woman, at the bottom of the page is “Important Safety Information 
About Yaz.” Below that is the following, with the text manipulated by formatting each 
line differently, as it is in the advertisement: 
What are the risks involved with taking any oral contraceptive (OC)?  OCs can be 
associated with increased risk of several serious side effects. OCs do not protect 
against HIV infections or other STDs. Women, especially those 35 and over, are 
strongly advised not to smoke because it increases the risk of serious 
cardiovascular side effects including blood clots, stroke, and heart attack.  
 
The formatting of this section is as interesting as the word choice. The designers of the 
advertisement emphasize that the serious side effects are a risk involved with taking any 
oral contraception. While this is true, the wording demonstrates a reluctance on the part 
of Yaz to take responsibility for these particular side effects. The ad also uses the 
conditional phrase ‘can be,’ instead of stating that “OCs are associated with increased 
risk of several serious side effects.” Both statements are true, but only one increases a 
consumer’s confidence in a medication.  
Additionally, after the warning points out that birth control pills “can be” 
associated with serious side effects,” they fail to list any of those side effects. Instead, the 
warning shifts the reader’s attention to an entirely separate issue, pointing out how OC’s 




information is true as well, STDs are not a side effect of birth control pills, they are a side 
effect of unprotected sex.  
Following the non sequitur regarding STDs, the warning returns to a “serious side 
effect” of OCs, cardiovascular issues. Here Yaz continues to diminish its culpability in 
these risks by emphasizing that the risk of cardiovascular side effects is something that 
only applies to women who smoke, “especially those 35 and over.” Many women 
interpret this phrase in the very manner that the advertisers want them to- that women are 
not at risk unless they smoke and are older. Unfortunately, all women who take birth 
control pills are at risk for cardiovascular side effects, including blood clots, heart attack, 
and stroke. And women who also have an inherited thrombophilia are at a much higher 
risk- in many cases, without even knowing it.  
The second page (Figure 3.2) makes the claim that Yaz can treat premenstrual 
symptoms including the ability to “help keep your skin clear.” According to the 
advertisement, this has been demonstrated in non-specified recent studies where “9 out of 
10 women saw improvement in their moderate acne.” This page also discusses the risk of 
increased potassium that is a side effect unique to Yaz. So, in addition to the side effects 
related to regular hormonal birth control pills Yaz, despite its popularity, carries 
additional risk factors. Why would a woman choose a birth control pill with more side 
effects over one with fewer? Perhaps because the claims of benefits are overstated while 




















FIGURE 3.2:  PAGE 2 OF YAZ ADVERTISEMENT 
 
The final page is a “Brief Summary Patient Package Insert.” (see Appendix A). 
The page consists of three columns of text in an extremely small, almost unreadable font. 
Approximately two thirds of the way down the first column, the advertisement states that 
women “should understand the benefits and risks of using the Pill” and that the 
information they provide “is not a replacement for a careful discussion” with a healthcare 
professional. 
On this page, Yaz does list blood clots as a risk and mentions that clotting 




the page. Under that information, in a separate box and in bold font, is a similar 
disclaimer to the one found on the front page regarding increased risks of women who 
smoke. While it is true that the risk of blood clots for women who smoke and/or are over 
35 is increased, the risk for women with clotting disorders is also greatly increased yet 
this information is not highlighted. Moreover, women who are over 35 and/or smoke are 
aware that they are over 35 and/or smoke, while most women with inherited 
thrombophilia are not usually aware they possess this mutation.  
Though clotting disorders are listed as an increased risk factor, the symptoms of 
blood clots are not addressed. Further down, the advertisement does state that information 
about symptoms is included with the prescription. It also states that women should 
“notify your healthcare provider if you notice any unusual physical disturbances while 
taking the pill.” This recommendation is buried in the middle of the page in barely 
readable font, likely to downplay the seriousness of the side effects. If they were to print 
in bold boxed letters to contact a doctor immediately at the onset of symptoms, it may 
make the medication appear more dangerous. And the statement is too broad to be of any 
use to most women, especially a woman who experiences major symptoms during an 
evening, weekend, holiday, or any other time her health care provider cannot be reached.  
Overall, the Yaz advertisment avoids taking responsibility for cardiovascular side 
effects by using conditional language and inculpating all other oral contraceptives. Also, 
the advertisement intentionally shifts the focus away from serious side effects by placing 
a disclaimer about STDs in the middle of the warning. It mentions clotting disorders but 
provides no indication that women could have a clotting disorder and be unaware of it.  




does not provide women with adequate guidance should they experience serious side 
effects. Perhaps the most disturbing inadequacy is the advertisement’s misleading 
implication that clots are only a risk to those over 35.  
It should be noted that during the course of this study, the Food and Drug 
Administration has required Bayer to run advertisements to correct previous Yaz 
marketing. “Regulators say the ads overstated the drug’s ability to improve women’s 
moods and clear up acne, while playing down its potential health risks” (Singer). 
Television commercials for Yaz have already been amended and updated print 
advertisements are scheduled to appear in forthcoming national magazines. According to 
The New York Times, in addition to the $20 million corrected advertisement campaign, 
Bayer has agreed to submit all Yaz ads for federal review for the next six years. The 
previously mentioned sales increase of Yaz in the United States from $262 million to 
$616 million occurred during the misleading advertising campaign (Singer). 
 
Lybrel 
The second advertisement is for Lybrel, a birth control that proclaims that it 
“makes it possible to go without your monthly period.” This advertisement was taken 
from the March 2008 issue of Cosmopolitan magazine, the best-selling magazine for 
young women (ages 18-34), according to www.cosmomediakit.com. This advertisement 
is one page with print on the front and back.  The bottom of the back page lists a revision 

















FIGURE 3.3:  PAGE1 OF LYBREL ADVERTISEMENT 
 
On the first page of the advertisement (Figure 3.3), toward the bottom left part of 
the page, there is a barefoot woman standing with arms outstretched behind her as the 
wind appears to blow back her skirt and fabric she is holding. Her head is tilted upward 
toward the sky and she is smiling. The visual rhetoric of this image suggests that the 
woman is happy and free. The title reads “Take a look at Lybrel” with the subtitle “Birth 
control that makes it possible to go without your monthly period.” Presumably this is 




The textual information for this advertisement is presented in question/ answer 
format. This gives the impression that Lybrel is open to addressing any concerns about 
their product. The format also allows Lybrel to play two roles in the advertisement- the 
role of the questioner and the role of the answerer. By presenting information this way, it 
conveniently entitles them to provide the information they choose with the appearance of 
two entities participating in the exchange. The format encourages women to put 
themselves in the role of the questioner, leaving an imagined expert in the role of the 
answer provider. By carefully masking that both roles are a creation of Lybrel, the 
advertisement creates the sense of a conversation with a trusted professional, as opposed 
to a sales pitch.  
The first question, “What is the Lybrel difference?” describes how Lybrel is the 
“first and only” FDA-approved birth control pill that you can take all year and not 
menstruate. Under this, the advertiser uses qualifying language to discuss the side effect 
of breakthrough bleeding. Here, the advertisement uses conditional language and then 
couches it with a disclaimer: “for some, this [breakthrough bleeding] may continue, but 
regardless… Lybrel remains highly effective birth control.” This sentence indicates that 
women should dismiss bleeding because Lybrel still works despite that side effect. Never 
mind that the very marketing for this pill is based on women taking it to avoid being 
inconvenienced by a period.  
The second question asks “Is it OK to not have my period?” According to the 
advertisement, “many health care professionals agree” that it is fine to not have a period 
while using OC. Nowhere does it state how many or which health care professionals, but 




says it is fine, if you don’t believe me, just ask your doctor.” This is followed by the 
prompt “How do I learn more about LYBREL?” that encourages women to seek out this 
medication.  
On the left side of the advertisement is a column of text titled “Important Safety 
Information” bolded and in all capital letters. Under that, also in bold is the disclaimer 
that the pill does not protect against STDs. Then below that in standard font: 
Some women should not use the Pill, including women who have blood clots; 
breast, uterine, or liver cancers; a history of heart attack, stroke, or breast 
cancer; and those who are or may be pregnant. Serious risks associated with the 
Pill which can be life threatening, include blood clots, stroke, and heart attacks. 
 
By stating that women “who have blood clots” should not use the Pill, this warning 
suggests that as long as a woman does not currently have a clot, she can use this 
medication. Also in this section, more conditional language is used: “which can be life 
threatening.” Though this study cannot state with absolute certainty, after considerable 
research and personal experience, this researcher has found that all blood clots, especially 
those causing strokes and heart attacks, are actually life threatening. 
Following that disclaimer, and underlined, is the warning that cigarette smoking 
increases the risk, especially in women over 35. Here the warning is worded as “serious 
adverse effects on the heart and blood vessels.” By using this phrasing in the warning, 
they have effectively decreased the understanding that smoking and age increase the risk 
of blood clots, heart attack, and stroke. While it may be clear to some that “adverse 
effects on the heart and blood vessels” are blood clots, heart attack, and stroke, many 




 At the bottom of the front page, the advertisement asks women to “Please see 
Brief Summary of Patient Information on the adjacent page.” This information is printed 
on the back of the advertisement in smaller but readable font (see Appendix A). At the 
top of this page in bold is another warning about birth control pills not protecting against 
sexually transmitted diseases. About one third of the way down the page is the warning 
that although most women can take oral contraceptives safely, “there are some women 
who are at high risk of developing certain serious diseases that can be life-threatening or 
may cause temporary or permanent disability or death.” Once again, the risk information 
is presented using conditional language: “some women,” “certain diseases,” “can be life-
threatening,” and “may cause temporary.”  
This section then lists with bullet points the risk factors for serious side effects 
including “have high blood pressure, diabetes, high cholesterol, or a tendency to form 
blood clots, or are obese” and “have or had clotting disorders, heart attack, stroke, etc.” In 
addition, “have headaches with neurological symptoms” is listed as a high risk factor. 
This is relatively new medical information that is further discussed in the next section of 
this manuscript.   
 Additionally, there is a box that is bolded with text explaining the increased risk 
for smokers, especially those over 35 years of age. Under that, it lists the serious side 
effects of the pill that “occur very infrequently, especially if you are in good health and 
do not smoke.” The advertisement does not list any of the symptoms of these side effects. 
But, it does recommend that women notify their healthcare provider if they notice “any 




 The Lybrel advertisement does list blood clots as a side effect of taking birth 
control pills, though on the front page where it warns against smoking, it describes the 
side effects more vaguely as “serious adverse side effects on the heart and blood vessels.” 
On the back page, the advertisement does warn that their product is not for women who 
have tendencies to form blood clots or “have or have had clotting disorders.” 
Unfortunately, there is no indication that a woman may not know she has a clotting 
disorder as well as no symptoms of the serious side effects listed. Additionally, the weak 
recommendation that women should notify their health care provider should they notice 
any “unusual disturbances” undermines the seriousness of these side effects. 
  
Loestrin 24 Fe 
The third advertisement is for Loestrin 24 Fe and was collected from a student 
health center at a major university. The Loestrin 24 Fe flyer has the same dimensions as 
the other advertisements. It was distributed to the college, and is dated March 2008. This 
advertisement is one page, front and back, with the majority of the patient information on 
the back. It should be noted that though the front of the advertisement is dated March 
2008, the information on the back states “Revised November 2006.”  
The front page of this advertisement (Figure 3.4), on the left side of the page, 
shows a young woman, dressed like a college student in a t-shirt and jeans, her head 
tilted, looking at the camera. She appears confident and relaxed, like she might be getting 
ready to have a conversation with a friend. Her stomach is just slightly exposed, not 
enough to be considered tawdry, just enough to indicate the independence expressed in 

















FIGURE 3.4:  PAGE 1 OF LOESTRIN24 FE ADVERTISEMENT 
 
The majority of the advertisement targets Yaz and its sister pill Yasmin. The main 
title reads “Does your birth control pill contain a recommendation for a blood test?” 
According to this advertisement, “your doctor may ask you to get a blood test to check 
your potassium level” if you take Yaz. A blue rectangular box under the paragraph states 
“With Loestrin 24 Fe you don’t have to worry about a blood test” though most women 
would benefit from a blood test to determine their risk of experiencing blood clots when 




Finally at the bottom of the page “Important Safety Information about Loestrin 24 
Fe” is in bold letters. The safety warning reads: 
Oral contraceptives are not for everybody. Most side effects of the Pill are not 
serious and those that are, occur infrequently. Serious risks, which can be life 
threatening, include blood clots, stroke, and heart attacks, and are increased if 
you smoke cigarettes. Cigarette smoking increases the risk of serious 
cardiovascular side effects, especially if you’re over 35. Women who use oral 
contraceptives should not smoke. Some women should not use the Pill, including 
women who have or have had blood clots, certain cancers, a history of heart 
attack or stroke, as well as those who are or may be pregnant. The Pill does not 
protect against HIV or sexually transmitted diseases.  
 
Qualifying language like “most side effects… are not serious” and “occur infrequently” 
and “can be life threatening” is used to downplay the risks involved in taking this 
medication. And the sentence ends with the disclaimer that those risks are increased if 
you smoke cigarettes. Here the advertisers give women a controllable factor for the side 
effects, making it easy for them to inaccurately conclude that “I don’t smoke, so I’m not 
at risk.” As stated before, it is true that women who smoke are at an increased risk, but 
placing that information at the end of the list of serious side effects leads women to 
believe that if they do not smoke, they are not at risk.  
 On the back of the advertisement there is one column of fairly small, dense text in 
the middle of the page with plenty of white space on either side (see Appendix A). In this 
section the wording is, for the most part, the same as that used in the other 
advertisements. Here the advertisement states that blood clots are a side effect of taking 
birth control pills. Listed with bullet points are increased risk factors for serious side 




advertisement provides no information concerning the symptoms of these side effects. 
And only makes the same weak recommendation that the other advertisements make- that 
women should notify their healthcare provider if they notice “any unusual physical 
disturbances.”  
 
Summary of Advertisements 
 “Risk information typically is presented in often-ignored smaller print; as part of a 
large, undifferentiated block of text… or simply hidden in plain view… Even when found 
and read, risk information often is missing key pieces of information that consumers need 
to evaluate drug risks” (Davis 607). Unfortunately for women this seems to be the case 
with advertisements for oral contraceptives.  
Each of these advertisements do list blood clots as a side effect of their 
medication, however: Yaz and Loestrin 24 Fe infer that the risk is only for older woman 
and/ or those who smoke; Lybrel obscures the risk by referring to it as “adverse effects on 
the heart and blood vessels”; and all three use conditional qualifying language that has 
been shown to reduce the understanding of the risks associated with taking a medication 
(Davis 619).  
All three advertisements mention that “had or have had clotting disorders” is a 
condition that increases the risk of serious side effects. However, none of them list it on 
the front of their advertisements. And they do not make any effort to inform women that 
they could have a clotting disorder and be completely unaware of it. 
Additionally, none of the advertisements analyzed in this research explains 




in the event of a serious side effect, all three use the vague terminology of “unusual 
physical disturbances” as a condition for notifying a health care provider. And this 
information is buried deep in the dense portions of small text.  
The Lybrel and Loestrin 24 Fe advertisements contain more complete information 
about blood clots on the front page than Yaz, including descriptions of women who 
should not take the Pill. Perhaps this is one of the reasons the FDA found the Yaz 
advertisement lacking. But unlike Yaz and Lybrel, the Loestrin 24 Fe advertisement does 
not list migraines or “headache with neurological symptoms” as a risk factor, probably 
because this is relatively new medical information and their risk information was last 
revised in 2006, while the others were written in 2007. 
While the legal responsibilities of the advertisers seem to have been met by the 
admission in the advertisements that birth control pills can cause clots, their ethical 
obligation to customers is questionable. Clearly, Yaz failed to meet either, hence their 
reprimand by the FDA. Unfortunately, for consumers, the FDA ruling and subsequent 
fine is tantamount to a slap on the wrist. What Davis et al. conclude in their article from 
the Journal of Health Communication seems to be consistent with this research. 
Pharmaceutical advertisers “show little inclination to clearly and completely 
communicate the side effects of drug usage.” And as research has shown, this is 
dangerous because patients exposed to advertising for medications are requesting these 







TABLE 3.1:  ADVERTISEMENTS 





as a Risk 
Contacting 
Doctor 
Yaz Yes No Yes* Yes* 
Lybrel Yes No Yes* Yes* 
Loestrin24 Fe Yes No Yes* Yes* 
   *inadequate information 
 
WEBSITES 
Websites are an increasing source of information for many women. Warner and 
Procaccino found that among female Web users, 94% reported that they were likely to 
use the Internet as a source of health information (792). Additionally, they established 
that women who use the Internet often were able to answer their health questions with 
information found online (801). If women are making health care decisions based on 
what information they find online, it is even more important than ever to look at the 
accuracy of the sites providing health information.   
To choose three websites for comparison in this study, the term “birth control 
pills” was typed into four popular search engines (Google, AOL, MSN, Yahoo!). The 
table below shows the top displayed sites on January 29, 2008. All “sponsored” sites, 









TABLE 3.2: CROSS REFERENCE OF SEARCH ENGINES 
SITE AOL GOOGLE MSN YAHOO! 
www.healthywomen.org x x x x 
www.fwhc.corg x x  x 
www.mayoclinic.com  x x x x 
www.plannedparenthood.org x x x x 
www.youngwomenshealth.org x x  x 
www.wdxcyber.com x x   
www.brown.edu x x x x 
www.acog.org x x   
kidshealth.org x x  x 
www.birthcontrol.com x  x  
www.birthcontrolbuzz.com   x  
www.birthcpills.com   x  
www.mybirthcontrolstore.com   x  
www.webmd.com   x x 
www.wikipedia.org   x x 
medicinenet.com    x 
 
Of the four matches that spanned all of the search engines the three selected for 
analysis were healthywomen.org, mayoclinic.com, and plannedparenthood.org. The 
Brown University site was found further down the search results than the other three 
sites, so it was eliminated. Additionally, when searching for information regarding birth 
control pills, the assumption could be made that the Brown University page was 
specifically for their students, and not necessarily relevant for other women. 
 Each site was given a cursory examination for usability based on Nielsen’s Ten 
Usability Heuristics. Then, they were examined for language, content, and the accuracy 








 Healthywomen.org is a website run by the National Women’s Health Resource 
Center, a non-profit organization that “has helped women be informed health care 
consumers and has supported and promoted major milestones in the advancement of 
women’s health for the past two decades.”  The page on this site that was located by the 
search engines (http://www.healthywomen.org/healthtopics/birthcontrolpills) is a “Health 
Topics” page about birth control pills. 
Based on Nielsen’s criteria, the site appears to be fairly well organized, with the 
exception of being a little cluttered (see Figure 3.5). The language used is consistent with 
“real-word conventions” and remains consistent throughout the webpage. Medical terms 
without a more common equivalent like “ectopic pregnancy” and “amenorrhea” are 
hyperlinked to a small pop-up box that define them. A column on the right side of the 
page includes links to different sections of that page, links to related stories, and a place 
to ask questions. There is also a place on the left side of the page titled “Related 
Resources,” with links to books, news, web sites, etc. By providing sources for the 






FIGURE 3.5: BIRTH CONTROL PILL PAGE FROM HEALTHYWOMEN.ORG 
 
 
The first section, which might be considered an overview or introduction about 
birth control pills (though it is not labeled as such), contains two interesting parts. The 
following information is in the first paragraph: 
Despite the fact that they are safe for most women, however, BCPs do carry some 
health risks. For example, if you are over 35 and smoke or have certain medical 
conditions such as a history of blood clots or breast or endometrial cancer, your 





While this warning is accurate, their example of “if you are over 35 and smoke” could 
lead younger, non-smokers to believe that there is no risk for them. Since most women 
begin taking birth control pills before the age of 24, many may dismiss this warning as 
not pertaining to them. And while it is important that they mention a history of blood 
clots as a warning, many women who have FVL have no family history indicative of this 
risk. 
 The second part of the opening section incorrectly states: 
In recent years, birth control pills have been changed to include less hormones, 
resulting in fewer side effects. In fact, all healthy women who don't smoke may 
use birth control pills, regardless of their age. 
 
While many birth control pills have no side effects in certain women, all birth control 
pills have dangerous side effects. And furthermore, there are no pills that “all healthy 
women who don’t smoke” may take. I can only assume that the mythical “safe pills” the 
website is referring to are progestogen based pills, which are commonly thought to be 
safe for women who cannot use estrogen. However, “studies have shown that both the 
estrogen dose as well as the progestogen type of oral contraceptives contribute to the 
increased risk of venous thrombosis in oral contraceptive users” (Vliet 563). 
 Further down the page, the site lists different types of pills and their possible side 
effects. Under the heading “Combination Pills,” three different types are listed, all 
containing estrogen. Following a short description of each type of pill is a list of 
advantages, disadvantages, and possible side effects, in that order. Fifteen advantages are 




finding this is no longer a benefit of the pill, since recent studies indicate that taking the 
pill increases the risk of other types of cancer including breast cancer (Szabo).  
 Only four disadvantages are listed: 
• could cause nausea, vomiting, headaches and/or spotting, particularly with 
the first few cycles 
• may lead to hypertension (less than one in 200 women) 
• may causes blood clots in a small percentage of users 
• may contribute to the formation of gallstones and rare benign liver tumors 
 
All of the disadvantages of taking the pill are tempered with qualifying conditional terms 
like “may contribute to” and “could cause.” Each of the disadvantages is further modified 
to appear less dangerous by adding phrases like “in a small percentage of users” to the 
thrombosis risk and “rare benign” to the liver tumors risk.  
 Contrarily, these same qualifying phrases are not used to describe the benefits. 
Certainly birth control pills do not improve acne, have beneficial effects on cholesterol, 
and decrease pain and cramps in all women. Why should the advantages be described as 
benefits applicable to every woman who takes the pill, but the disadvantages are 
relegated to just a select few? This practice of using qualifying languages is perhaps not 
surprising when used in pharmaceutical advertising, after all, it is in their best interest to 
provide the most optimistic view of their product and therefore increase profits. However, 
this use of qualifying language on a not-for-profit website that claims to provide women 
with accurate health care information is questionable.  
 Toward the end of the web page is a section called Health benefits, risks and 
other medical issues about birth control pills. In this final section, the website does a 
much better job of addressing the risks. Here, the site discusses ischemic strokes, VTEs, 




This rare condition causes clots to form in your blood vessels and can cause 
symptoms including pain, swelling, and varicose veins, and may block the flow of 
blood. The risk may vary with the type of progestin used in the pill. 
 
The mention of risk with progestin pill is surprising since earlier on the page, the site fails 
to include VTE as a risk with progestin pills. It is also unfortunate that they list VTEs as a 
“rare condition,” since according to the U.S. Surgeon General they affect as many as 
600,000 people a year. And also unfortunate is the site’s description of the symptoms of a 
blood clot, which fail to address symptoms that indicate anything other than a deep vein 
thrombosis.  
In addition to listing VTEs as a risk when taking birth control pills, 
healthywomen.org also lists having migraines as increasing the risk of stroke: 
Migraines and stroke. Women who take oral contraceptive and have a history of 
migraines have an increased risk of stroke compared to nonusers with a history of 
migraine. Your risk is greatest if you have migraines with "aura"--neurologic 
symptoms related to vision, such as blurred vision, temporary loss of vision or 
seeing flashing lights or zigzag lines. As a result, both the American College of 
Obstetricians and Gynecologists (ACOG) and the World Health Organization 
(WHO) have concluded that for women over age 35 who get migraines, the risks 
of BCPs use usually outweigh the benefits. 
 
This information is only partly accurate. However it fails to mention that, according to 
the World Health Organization, women who suffer migraines with aura should not take 
birth control pills at any age (Allais S12). The way they phrase the warning leads women 





Overall, healthywomen.org does list blood clots as a side effect of birth control 
pills. However, the site fails to address clotting disorders, or to properly explain the 
symptoms of a blood clot, listing only those associated with DVTs. The site does not 
emphasize the dangers of blood clots and, consequently fails to advise women what to do 
if they have a clot. It also perpetuates the myth that certain risks are only associated with 
older women. Regrettably, this website designed to serve the interests of women 
downplays the risks of birth control pills in favor of highlighting advantages that may or 
may not be applicable for any women, let alone most women.  
 
www.mayoclinic.com 
 The Mayo Clinic is self-described as “the world’s first and largest integrated, not-
for-profit group medical practice.” The second most popular webpage, after cross-
referencing search engines, is their “Birth control pill FAQ: Benefits, risks and choices” 
(http://www.mayoclinic.com/health/birth-control-pill/WO00098) page. As the title infers, 
this page is set up in a question and answer format. At the bottom of the page, there are a 
series of links under the title “Related.” The site appears to meet Nielsen’s criteria for 
usability, with the aesthetics of the page’s minimalist layout (see Figure 3.6). The 
information is written in terms familiar to most readers and is consistent throughout the 





























FIGURE 3.6: BIRTH CONTROL PILL PAGE FROM MAYOCLINIC.COM 
 
This page appears to be targeted toward women who are already on birth control 
pills, as is indicated in the first paragraph: 
If you use the birth control pill — that is, an oral contraceptive — you're probably 
happy with its convenience and reliability. Still, you may have many questions 
about the potential effects of birth control pills on your overall health. Here's 
what Mayo Clinic specialists have to say about women's health and oral 
contraceptive use. 
The first ten questions address concerns that women currently taking birth control pills 
may have. In fact, out of the 17 questions on the webpage, only five address adverse side 




cancer, cholesterol levels, blood pressure, and the final health question “What’s the risk 
of smoking if you’re over age 35 and taking birth control pills?”  
 Unfortunately, the smoking question is the closest this site gets to informing 
women about the risks of blood clots. The Mayo Clinic’s response to the question is 
simply that smoking can increase the risk of cardiovascular disease. And by phrasing the 
question on their information page about “Benefits, risks, and choices,” the brief nod the 
site gives to cardiovascular issues is just another example of attributing the dangers of 
birth control pills only to those who smoke and/or are over 35.  
Nowhere on this page does it mention thrombosis as a risk when taking birth 
control pills. Therefore, it’s not surprising that the site also fails to mention anything 
about clotting disorders increasing the risk of blood clots, the symptoms of a blood clot, 
or what a woman should do in the event of a blood clot. Even the related links at the 
bottom of the page do not give women the opportunity to find more information about 
risks involved with taking birth control pills. Overall, this site fails to adequately inform 
women of any risks associated with taking birth control pills and is a poor representation 




 The Planned Parenthood site is the third site that was reviewed. According to this 
site, Planned Parenthood “is the nation’s leading sexual and reproductive health care 
advocate and provider.” As listed on this website, Planned Parenthood offers “medically 





4228.htm).   
 The design of this website meets Nielsen’s usability criteria. The page layout is 
simple and easy to navigate. It links relevant text to similar pages to give readers access 
to further information, making the site flexible and efficient. At the top of the page is a 
link entitled “Legal Disclaimer” which leads to the warning “Information Obtained 
Through the PPFA Web Site Does Not Constitute Medical, Legal, or Other Professional 
Advice.”  
FIGURE 3.7: BIRTH CONTROL PILL PAGE FROM PLANNEDPARENTHOOD.ORG 
 
On the left side of the webpage are links to information about other birth control 
options. Just under the title of the Birth Control Pill page there is a “Quick Facts” box 




effective, and convenient” with each of those terms linking to a spot further down on the 
same page. Following the “Quick Facts” box is an introductory paragraph and a 
“Highlights” section with bullet points that link to each different section of the webpage.  
Each of the following sections are formatted as question and answers.  
 Under the “How Safe Are Birth Control Pills?” section, the first paragraph states, 
accurately, that most women can use birth control pills safely. The second paragraph 
informs women that all medications have risks and that “Certain conditions” can increase 
those risks. “Certain conditions” is hyperlinked to a page titled “Who Can Take Birth 
Control Pills?”  
  This page lists conditions in which a woman should not take birth control pills. 
Among these conditions is “have certain inherited blood-clotting disorders.” It further 
states that women with clotting problems should not take birth control pills, even 
progestin-only pills, and that migraines increase the risk factors. At the end of this page, 
there is a link to “other methods” of birth control. 
 Under the “What Are the Benefits of Birth Control Pills?” section, Planned 
Parenthood states that birth control pills can offer “some protection against” followed by 
a list including acne, ovarian cysts, etc. By using qualifying language in the benefits 
section of the birth control pill information, this site is offering women a more accurate 
interpretation of health benefits than if they had stated that birth control pills do prevent 
acne, ovarian cysts, etc.  
 Planned Parenthood splits the disadvantages information into two sections: 
“Possible Side Effects” and “Serious Side Effects.” Under the serious side effects, they 




risks, they list factors that increase those risks, including “certain inherited blood-clotting 
disorders.” 
 Also in the serious side effects section, the site lists warning signs and suggests 
that women report any of the warning signs to their doctor as soon as possible. The list of 
warning signs includes symptoms of strokes, breast cancer, heart attack, pulmonary 
embolism, and deep-vein thrombosis, as well as others.  
 Impressively, the Planned Parenthood site seems to clearly and accurately present 
information about birth control pills. The risk of thrombosis is stated and thrombophilia is 
mentioned as a precaution. The site also describes the symptoms of a blood clot and 
instructs women to contact their doctor should they have any symptoms. Additionally, the 
site fairly represents the benefits and other risks of taking birth control pills.  
The Planned Parenthood site could be improved by linking the phrase “certain 
inherited blood-clotting disorders” to a page that more thoroughly discusses 
thrombophilia. They could emphasize that women with symptoms should seek medical 
attention immediately. The phrasing “report any signs to your health care provider as 
soon as possible” could be misinterpreted that you should tell your doctor at your next 
appointment, instead of that you should see a doctor or go to the hospital immediately. 
These suggestions aside, the Planned Parenthood webpage on birth control pills lives up 
to their claim to provide “medically accurate information.” 
 
Summary of Websites 
 Despite all ranking high on popular search engines, the sites reviewed vary 




Clinic’s website is the most lacking, with no meaningful risk information of any kind. On 
the other hand, at least it does not provide inaccurate and conflicting information like 
healthywomen.org. Healthywomen.org did warn women that blood clots are a risk factor 
when taking birth control pills, but it overstated their health benefits. And it perpetuated 
the misconception that only older women or those that smoke are at risk when taking 
birth control pills.  
 The Planned Parenthood site, the only site with a legal disclaimer to let women 
know their information was not a substitute for medical counsel, had the most accurate 
information. Ironically, the other two sites listed inadequate and even incorrect risk 
information yet provided no such disclaimer. Of course, there is always room for 
improvement, particularly with regard to informing women about inherited 
thrombophilia. However, when compared to the other sites in this study, the Planned 
Parenthood is unquestionably the best source of risk information.  
TABLE 3.3:  WEBSITES 





as a Risk 
Contacting 
Doctor 
Healthywomen.org Yes Yes* No No 
Mayoclinic.com No No No No 




 Pharmaceutical inserts were collected and analyzed for three different types of 
birth control pills (see Appendix A). These materials were obtained from women who 




January 2009.  The inserts were acquired in this manner to ensure that they are an actual 
representation of what women receive with their prescription. 
 
Nortrel (norethindrone and ethinyl estradiol tablets, USP) 
 The Nortrel tablets are produced by Barr Laboratories, Inc. and the prescription 
was filled at a student health center on the campus of a major university. The pill insert 
has a revision date of March 2005. The insert folds out to a single piece of paper about 12 
by 17 inches, with a 12 by 4 inch section separated by perforation. This smaller section is 
perforated and labeled “Brief Summary Patient Package Insert” and has text on the front 
and back of the page.  
On the main section of the insert, there is also text on the front and back. The text 
on the front is dedicated to precautions for taking the pill. Like in the advertisements, the 
risk of blood clots in women over 35 who smoke is highlighted with bold, boxed text. 
Under the heading “Who Should Not Take Oral Contraceptives:” it states “you should 
not use the pill if you have any of the following conditions” followed by a list including a 
history of heart attack or stroke; blood clots in the legs, lungs or eyes; or a history of 
blood clots in the deep veins of your legs. This information could lead one to believe that 
you are only at risk, had you ever previously suffered from any of these conditions. It 
fails to list any information about family history or clotting disorders. The insert also fails 
to list migraines with aura under these conditions, but does list it as a condition to speak 
to your health care provider about before taking OC.  
Further into this section is a chart that estimates the risk of death from birth 




not provided in a chart, only in the middle of a brief and dense paragraph under “Risk of 
developing blood clots.” Under, the chart is a “Warning Signals” section that lists 
symptoms of blood clots, including those for stroke, deep vein thrombosis, heart attack, 
and pulmonary embolism. If any of these symptoms occur, the manufacturer advises you 
to call your doctor immediately. All of this information is listed in the same font. Only 
the section headings are bolded.  
The smaller section is perforated, presumably so women may tear it away from 
the larger section to keep. The majority of the smaller section, approximately three 
quarters of the text, is dedicated to instructions for how to use the pill, including what to 
do if you miss a pill. The remaining quarter is an abbreviated warning. This warning does 
mention clotting disorders and risk of blood clot. However, there is no mention of 
symptoms. And as far as what to do if you experience symptoms, the inserts use the same 
weak language from the advertisements, to “notify your doctor” if you have “unusual 
physical disturbances.”  
Overall, the Nortrel insert contains all four pieces of information: blood clots are a 
risk; clotting disorders increase this risk; symptoms of a blood clot; and contact a 
healthcare provider in the event of these symptoms. However the main portion of Nortrel 
insert fails to list clotting disorders as an increased risk factor. While the smaller section, 
the one perforated to make it easy to keep, fails to list symptoms of a blood clot and 







Tri-Sprintec 28 (norgestimate and ethinyl estradiol tablets) 
 The Tri-Sprintec tablets are also produced by Barr Laboratories, Inc. and this 
prescription was filled at a CVS pharmacy in Tallahassee, Florida. Though similar in 
appearance to the Nortrel, and from the same manufacturer, this pill insert has a revision 
date of February 2004.  
 Even though the Nortrel was revised over a year after the Tri-Sprintec 28 revision, 
the warning information is exactly the same. The only differences between the two inserts 
are the logos and chemical make up of each set of pills. Clearly the manufacturer did not 
see any reason to make any actual changes to the warning information from 2004 to 
2005. They also felt no need to update the information for these prescriptions with any 
new information from the past four to five years. Hence no warning about migraine with 
auras despite the fact that, as previously mentioned, the World Health Organization stated 
“that women suffering from migraine with aura at any age should never use oral 
contraceptives” (Allais S12). Perhaps it was not cost effective to update these leaflets 
 
Loestrin 24 Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous 
fumarate tablets) 
 The Loestrin tablets are produced by Warner Chillcott and this prescription was 
filled at a student health center at a major university. The pill insert is dated September 
2007 and measures 11 by 20 inches. A portion (3 by 20 inches) of the insert is perforated, 
presumably so the patient can remove this section to keep.  
 The font used for this insert is larger than the font of the other two inserts, with 




information contained in the insert is formatted almost identically to the other two. Like 
the others, in the main section the risk of blood clots in smokers who are over 35 years of 
age is in a separate box from the other warning information and is in bold font. Indicating 
that women who are over 35 or smoke are those who should receive the most emphasized 
and therefore visible warning information.  
One difference can be found under the “Who Should Not Take Oral 
Contraceptives” section. Here Loestrin24 Fe lists seven more conditions than the other 
inserts, none of which concern cardiovascular conditions. This insert fails to list a family 
history of blood clots or clotting disorders as an increased risk factor. Unfortunately, the 
advisement that women should not use the pill if they have or have ever had a history of 
blood clots, could lead women to believe that if they have never had a blood clot, then 
they are not at an increased risk.  
Though from a different manufacturer, the rest of the materials in the insert are 
nearly identical, including the warning signals. Like the other two inserts, the smaller, 
tear-away section lists clotting disorders as an increased risk factor. But also like the 
other inserts, it fails to list the symptoms, referring to the main section that was 
presumably disposed of by the women who tore off the perforated section to keep.   
 
Summary of Inserts 
 In conclusion, all of the birth control inserts have the same strengths and 
weaknesses, though the Loestrin24 Fe provides the information in larger font that is much 
more readable than Nortrel and Tri-Sprintec. These inserts also offer considerably more 




of the inserts lists all four points of information that were examined in this study. 
However, clotting disorders are only mentioned in the smaller sections, while symptoms 
of blood clots are only listed in the larger sections. This means one would have to 
thoroughly read both sections of the inserts to obtain all of the risk information- 
something that is unlikely due to the redundancy of much of the rest of the information.  
Each insert has statistical information about the risks involved with taking the 
medication but without the disclaimer that it is based on studies run by the very company 
who makes the birth control pill. There is actually no mention about what studies have 
provided this information. Kemmerman et al. found that studies funded by 
pharmaceutical companies that make oral contraceptives produced more favorable results 
than independent studies of the same medications (133). And as previously mentioned, it 
is not likely that most women would even understand the statistics presented. The recent 
study by Gigerenzer et al. demonstrated the statistical illiteracy of most patients and, 
more alarmingly, their physicians.  
Besides the typical problems with understanding medical warnings (tiny print, 
obscure statistics), these inserts fail to make clear the increased risk of blood clots due to 
clotting disorders. The pharmaceutical manufacturers need to use language that not only 
more clearly defines risks and symptoms of blood clots, but also indicates that there is a 
possibility that women may have a clotting disorder and be unaware.  
 Finally, one of the central tenets of technical communication is to consider your 
audience and design accordingly. As Schriver points out in Dynamics in Document 
Design, “Since people rely on documents to make decisions that influence their safety, 




making textual choices- in deciding what to say and what not to say” (11).  By creating 
documents that are so text heavy, with dense language couched in conditional terms, in 
font barely large enough to read, pharmaceutical companies are clearly not designing for 
their audience, or any audience for that matter. But perhaps that is their intention. 
 
TABLE 3.4:  PHARMACEUTICAL INSERTS- MAIN SECTION 





as a Risk 
Contacting 
Doctor 
Nortrel Yes Yes No Yes 
Tri-Sprintec 28 Yes Yes No Yes 
Loestrin24 Fe Yes Yes No Yes 
 
 
TABLE 3.5:  PHARMACEUTICAL INSERTS- SMALL SECTION 





as a Risk 
Contacting 
Doctor 
Nortrel Yes No Yes Yes* 
Tri-Sprintec 28 Yes No Yes Yes* 




 This analysis of the media used to communicate risk information about side 
effects of birth control pills found that it would be very difficult for women to find 
exceptional sources of information. In many cases, it would difficult to for them to find 
even adequate information. For example, the risk information communicated in 




of side effects when smoking and/or over the age of 35 and the lack of protection from 
STDs are the only risks that are highlighted. This could be due to the increased risk factor 
from smoking, but it may also have to do with perception of message. Darren Shickle, in 
his article “On a supposed right to lie [to the public] from benevolent motives”: 
Communicating health risks to the public, mentions risk factors that are perceived by the 
public as more worrying. Chief among them is if a risk is “involuntary (e.g. exposure to 
pollution) rather than voluntary (e.g. smoking)” ( 245). Is it possible that pharmaceuticals 
want to emphasize the increased risk factors associated with taking birth control pills and 
smoking, thereby deemphasizing involuntary risk factors like clotting disorders? 
 Websites, claiming to be non-profit sources of information for women often list 
incomplete information, or in the case of healthywomen.org, inaccurate information. 
They use conditional terms that seem to favor birth control pills, while claiming only to 
have an agenda to help women make educated decisions about their health. Much of their 
warning information is similar to that found in the inserts and advertisements produced 
by the pharmaceutical companies themselves, certainly not a neutral source. 
In their inserts, pharmaceutical companies couch their risk information in text 
heavy documents of barely readable font full of conditional language. Like the 
advertisements, they highlight only controllable risk factors. These inserts are created to 
be accountable to their legal teams but not to their patients. 
With the exception of PlannedParenthood.org, all of the media analyzed here was 
lacking adequate, and in some cases accurate information about blood clots, their 







After demonstrating the limited information available to women in the media 
analysis, this survey attempted to discern what women actually know about blood clots 
and clotting disorders. The survey included 23 questions (multiple choice, fill-in-the-
blank, ranking) and one open-ended comment section, and assessed what women know 
about the risks of OC. The survey was broken down into 5 sections (“pages”) and was 
hosted on SurveyMonkey.com. The first page, titled “Survey Information,” was an IRB 
approved disclaimer and contained no questions. The second page was titled “Birth 
Control Pill Survey,” contained six questions, and asked when, where, and why women 
were prescribed birth control pills. This page also contained a question about whether 
healthcare providers offered women other options besides birth control pills. 
 The third page of the survey was entitled “Risks” and contained questions about 
the women’s interactions with pharmacists and their healthcare providers with regard to 
risk information. This section also contained two questions to gauge the women’s 
understanding of which health risks are associated with taking birth control pills. Women 
were asked to select which health risks out of 11 possible choices are associated with 
birth control pills. The list of health risks used for this survey was taken primarily from 
Bryden and Fletcher’s 2001 study; though for this survey, women were also given the 
option to select “None of the above” or “Don’t know.”  
 The fourth page of the survey, “Communication,” asked the women three 
questions about their behavior concerning the information that accompanies their 




 The fifth, and final, page of the survey was called “Awareness,” contained eight 
questions and a final comment section. These questions addressed whether the women 
were familiar with inherited thrombophilia (i.e. FVL), familiar with the symptoms of 
blood clots, and whether they would be willing to take a blood test to assess their own 
risk for clots.  
 
PARTICIPANTS 
The survey was created using Surveymonkey.com and then tested by a usability 
professional. Her suggestions, mostly changes in wording for clarification, were put into 
place. The survey went live at approximately 12:30pm on Tuesday, February 10th. 
Responses were solicited through email networking and the website Facebook.com. Due 
to the subject matter, response to the survey was staggering and immediate. After being 
posted for only four hours, 100 surveys had been completed. The survey remained live 
for 10 days, collecting at total of 325 surveys with only one participant that skipped all of 
the questions, and 311 that answered all questions requiring an answer.   
 
RESULTS 
Birth Control Pill Survey 
The average age of the women surveyed when they first began taking birth 
control pills was a little under 19 years (18.9). Of the 324 women who responded, only 
20 or 6% were over the age of 25 when they first began taking birth control pills. A little 





 Most of the women were prescribed birth control pills by their gynecologist 
(53.4%). A handful of the “Other” responses indicated that women had been prescribed 
OC by their dermatologist. One woman volunteered that she got them “from a friend.”   
 More than half of the women said the main reason they were prescribed birth 
control pills is because they asked for a prescription. And over thirty percent were 
prescribed them for reasons other than birth control (regulate periods, clear up acne, etc.) 
with one woman responding that the “Doctor suggested they would improve my skin (not 
true).” 
 When asked if their health care provider discussed any other birth control options 
with them, prior to prescribing the pill, five of the 324 women who answered could not 
remember. A handful of other women (8) felt that the question was not applicable to them 
because they were not prescribed the medication for birth control, or as the woman above 
stated, she got them from a friend. Of the remaining 311 women surveyed, 200 answered 
that their health care provider did not discuss other options with them.  
           












When asked whether their family history was taken prior to being prescribed birth 
control pills 85% responded yes, with 12 women choosing to skip the question. The 
majority of the women said that they filled out a form, while only 42.9% said they filled 
out a form and their health care provider discussed it with them (of 275 responses). 
Nineteen women chose the “Other” option on the survey with 8 who did not remember; 7 
said their doctors discussed it with them but filled out no form; 2 were adopted; 1 was not 
asked; and 1 said that her doctor knew her family as both her mother and grandmother 
were also his patients.          













When the women were asked to select which risk factors were associated with 
birth control pills, most women, 76.7% of the 313 who answered the question, selected  
blood clots. Weight gain, which is not considered a health risk or even a side effect of 
birth control pills, was the selection most chosen (79.9%).  
Of the risk factors listed in Figure 4.3 only the following are actually associated 
with taking OC: 
• Increased blood pressure 
• Nausea 
• Stroke 
• Increased risk of cervical cancer 
• Increased risk of breast cancer 
• Blood clots 
















Alarmingly, only seven women correctly chose all of the health risks. And of those seven 
women, six also selected options that are not health risks associated with OC. Therefore, 
only one woman out of 313 was able to correctly identify all of the risk factors listed.  
Thirty percent of the women surveyed believed that stroke and blood clots are 
only risk factors for women who are over 35 and/or smoke. A little over forty percent 
knew that all women are at risk, but only 5 of the 7 women who correctly chose the risk 
factors mentioned above selected this option. 
 When asked if their health care provider discussed the risks of taking birth control 
pills with them before giving them the prescription, 54.6% (out of 313) said yes and 38% 
said no. Six percent of women couldn’t remember. And one woman was “told to read the 
pamphlet for the pills to be aware of the risks.” But when asked if their pharmacist 
discussed the risks with them, a whopping 86.9% said no. One woman said, “I received a 
free sample so did not go to Pharmacy. Discontinued use on day 11 due to reaction to pill 
(stroke-like symptoms).” And another “They had me sign a release form confirming I had 
received counsel from them, but I really had not.” 
 
Communication 
Most women say they read the pharmaceutical insert that came with their birth 
control pills with 39% (of 313) claiming they read the materials thoroughly and 37.1% 
admitting they only glanced at the materials. The remaining women did not read the 
materials, read only the parts concerning missing a pill, or could not remember.  
 As far as materials from the pharmacy, 30.7% claimed to read them thoroughly, 




313 women received OC as a sample and 33 said no materials accompanied their 
prescriptions. When asked if they normally read the materials accompanying their 
prescriptions, only 30% said they read everything given to them. Nearly the same number 
(28.8%) said they only read the materials if they are unfamiliar with the medication. And 
11.5% said they don’t read the information, they trust their doctor or pharmacist to tell 
them the risks. One woman observed that she does not typically read the materials that 
come with her prescriptions as “It’s dense information and not presented in an easy-to-
digest format.” 
Awareness 
When asked if the women were aware of genetic conditions that increase the risk 
of blood clots 58.2% (of the 311 who answered) said no. The majority of women that had 
heard of clotting disorders did not know about them before they began taking OC. 
Therefore 82.6% of women were not aware of thrombophilia before they began taking 















Of the women who were aware, most say they were told by their doctors (27.7%). 
Others learned from a friend, read about it on the Internet, found out from the news, or 
learned about it in school (medical or otherwise). Twenty-one women had a family 
member or friend with a clotting disorder and two of the participants learned about 
clotting disorders because they had suffered clots, themselves. Interestingly, one woman 
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FIGURE 4.5: HOW WOMEN BECAME AWARE OF THROMBOPHILIA. 
 
 When asked whether they were familiar with the symptoms of a blood clot, most 
women (60.5% of the 311 who answered) admitted that they were not. Only 15.8% 
answered that they did know the symptoms with the remaining 23.8% unsure. When 
asked where they learned the symptoms of a blood clot, 9 of the 65 respondents answered 
that they did not know or weren’t sure. The remainder said they learned from reading 
pamphlets or on the Internet, from a friend, or because they are in the medical field. Eight 




a blood clot. And two participants said they had blood clots with one stating “When I 
experienced chest pain and did research online. It turned out that I had pulmonary 
embolisms (while on BCP).” Only 9% women reported learning about the symptoms of 
blood clots from their doctor. Ironically, more women know someone who has had a clot.  
 When the women were asked to rank where they were most likely to obtain 
medical information from, 54.5% listed their health care provider as their first choice. 
The Internet was the second most popular source of information with 37.8% listing it as a 
first choice and another 30% as a second choice. Friends and pharmacist were the least 
likely choices. 
 And finally, when asked if they would be willing to take a blood test to assess 
whether they were at an increased risk for blood clots, the women overwhelmingly said 
yes. Of the 311 who answered the question, 82.3% (or 256) said they would be willing to 
take the test. Only 7.2% said no, with the other 10.6% “not sure.”  








FIGURE 4.6: ARE WOMEN WILLING TO TAKE A BLOOD TEST TO ASSESS THEIR  
RISK OF BLOOD CLOTS? 
 
 
 To assess how willing women would be to pay for the blood test, they were given 
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FIGURE 4.7: WOULD WOMEN BE WILLING TO PAY FOR THE TEST? 
 
Of the 16 “Other” answers 11 answered yes with stipulations (cost, recommended by 
doctor, etc.). One woman said she would be willing to pay for the test if it were less than 
$250 while another said $150. The remaining five said they didn’t know if they were 
willing to pay for the test. Based on these results, if the blood test were under $20, 67.9% 
would be willing to take the test and pay for it. If over $20 but under $50, that number 
drops only to 64.1%.  













 In the final section, the surveyed women were invited to “share anything else 
about your experience taking birth control pills.” In this section, 81 women, or 26% of  
survey participants responded. Their answers varied from three word responses like 
“severe mood swings” and “had no problems” to 400 word essays. The average length of 
the responses was 3.3 sentences. I reviewed all the responses in this section and 
categorized each as either a positive experience with birth control pills, a negative 
experience with birth control pills, or neutral. Out of the 81 responses, 53% were 
negative, 15% were positive, and the other 32% were neutral.  
   







FIGURE 4.9: COMMENTS ABOUT EXPERIENCES WITH OC. 
 
Of the negative responses, four women experienced blood clots, or symptoms of 
blood clots (undiagnosed) when taking the pill. One woman mentioned a family history 
of blood clots, while another said that she stopped taking birth control pills because she 
was miserable and “because I learned of two friends who had strokes after taking a form 
of BC.” A third woman responded, “After I had been taking BC pills for about 3 month I 




LOVE it if there was a way for me to know how much at risk I am for something like 
blood clots.” 
 Most of the other negative responses were regarding other side effects of birth 
control pills, especially mood swings. Some of the more candid responses included “they 
made me a moody [expletive]!” Another expounded on her experience with the 
following: 
My experience on birth control pills, the Nuvaring, or Depo-Provera all proved to 
be horrendous… I think birth control pills came straight from hell and I hate, 
hate, hate it. I would rather undergo Chinese water torture daily than take birth 
control, and that is the God’s honest truth… My fertility has been affected forever 
by my under informed choice to go on birth control, and by the irresponsible 
doctors who encouraged me to switch methods rapidly “until I found what worked 
for me.” 
 
 Disturbingly, many of the negative responses focused less on the participants’ 
actual experience with birth control pills, and more on their experience with their doctors. 
Comments from these women included: 
• My current gynecologist completely downplayed any risks associated with 
hormonally-based birth control, so I do not trust her (or most doctors for 
that matter). 
 
• I wondered after being on the pill so long if there were any affects, but 
have had difficulty getting doctors to even discuss this. 
 
• It was never explained why the particular prescription I was given was 
chosen over other available options/ options were not described or 
discussed. 
 
• I’ve had two different GYNs give me completely contradictory information 




how little doctors seem to know about female BCP- I haven’t experienced 
this amount of ambiguity with any other medical specialty or problem. 
 
• I was shocked- and grateful- when I finally found a doctor who discussed 
alternatives with me, suggested a wide variety of reading, and let me do 
my own research and make my own decision before wiring[sic] a 
prescription. After doing the reading, there is no way I will ever take 
another birth control pill in my life. Every other doctor I had acted like it 
was giving out Altoids… 
 
• I think they’re too often the first option doctors prescribe for reasons other 
than birth control. That’s frustrating. They’re not a magic pill and some 
doctors seem to think they are. 
 
• No doctor ever talked to me about lots of options for birth control. It was 
just “you want the Pill? ok, here you go.” 
 
Neutral responses included women voicing their frustration with insurance 
companies who cover Viagra but not oral contraceptives; women who stopped taking the 
pill due to increased prescription costs; women who were making suggestions for future 
research; and other similar responses. One woman said: 
It regulated my menstrual problems well. I didn’t expect it, but I felt emotionally 
happier. Yet my closest friends and family complained that I was acting very 
strange and depressed. This is why I quite[sic] taking the pill.  
And another : 
I would be interested in learning about the number of women who have had 
miscarriages and the correlation[sic] with birth control and the length of time 
birth control was taken. There may be no correlation. But the number of women 
who have miscarriages is alarming. 
 





• I wasn’t told herbs can interrupt the pills and I have a Son to prove it. 
 
• I was not aware, in 2003, when I loaded up on vitamins and herbal supplements 
that they could change the effectiveness of the pill… hence, my son! 
 
The positive responses were often shorter like “Never had a problem” and “very 
positive experience.” One woman said: 
I’ve been really happy with the pill I’ve been on for years and years. I sometimes 
wonder if it will effect[sic] me having kids or any other negative side effects, but I 




I think the experience taught me to take responsibility for myself. My dad is the 
one who actually wanted me to start taking them and even though I was 16, it was 
a great choice. I am 25 and have never had a pregnancy scare, which is good for 
me because I am not ready for children right now.  
 
DISCUSSION 
 Overall, the results of the survey demonstrated that women do not clearly 
understand the risks involved with taking birth control pills. Many of them believe that 
certain risks are only associated with being over 35 years of age and/or smoking. This is 
not surprising given that only a little over half of the women reported their doctor 
discussing the risks with them before giving them a prescription. And for a majority of 
the women, their doctor never discussed other birth control options with them.   
 Most of the women were asked about their family history before being given a 
prescription, but fewer than half actually discussed it with their doctor. Almost none of 




third of the women actually read the risk information that accompanies their 
prescriptions. The majority of women were not aware of inherited thrombophilia and 
most are not familiar with the symptoms of blood clots. However, the great majority of 
women would be willing to take a blood test in order to assess their risk of forming blood 
clots.  
 For the most part, these results show what was expected. Most women do not 
fully understand the risks involved with taking birth control pills, they are not familiar 
with the symptoms of a blood clot, and they have never heard of clotting disorders. This 
is perhaps not surprising given the lack of information available to them, as found in the 
media analysis. The survey results confirm that there is a lack of communication about 
the risks of taking birth control pills, and virtually no communication about clotting 
disorders. More importantly, the majority of women who are taking a prescription that 
















 Certainly, the problem of inherited thrombophilia and the increased risks of blood 
clots when taking OC is a complicated one. There seems to be little consensus in the 
medical community about how to handle the issue. This investigation has demonstrated 
that little has been done to inform women of this potentially dangerous interaction. 
Clearly, most women are unaware of inherited thrombophilia, and therefore unaware of 
an increased risk when combined with estrogen. Based on my investigation, it appears 
that the communication breakdown is three fold.  Responsibility for such a complex 
problem lies on the shoulders not only of the prescriber of OC, but also the dispenser of 
OC, and on the patient.  Upon completion of this research it is apparent that there are 
several ways to improve communication regarding inherited thrombophilia and the 
dangers of oral contraceptives. 
 
PHARMACEUTICAL MANUFACTURERS RESPONSIBILITY 
Nearly 40% of the women surveyed in this study said they thoroughly read the 
pharmaceutical insert that accompany their birth control pills, with a further 37% 
reporting that they at least glance at the materials. If the majority (77%)  of women who 
take birth control pills are at least looking at the information that is provided with their 
prescriptions, improving this information in content and presentation could increase 
awareness of blood clots, their symptoms, and inherited thrombophilia.  And by doing so, 




Inserts for oral contraceptives should more clearly state that clotting disorders 
increase the risk of side effects and specify that women may have a clotting disorder 
despite no prior history or blood clots. Information about testing for these genetic 
conditions and encouraging women to discuss this with their doctors would also be an 
improvement. Additionally, the wording that women “should notify your healthcare 
provider if you notice any unusual physical disturbances while taking the pill” should be 
changed to a more proactive statement. For example “contact your healthcare 
professional immediately if you experience any symptoms of a blood clot listed above. If 
your healthcare provider is unavailable or your symptoms worsen, seek treatment at an 
emergency healthcare center.” And this information should be included on the small, 
perforated portion of the insert as well as the main section. 
As pointed out by one survey participant, the information in these inserts is 
“dense” and “not presented in an easy-to-digest format.” Combining poor usability with 
difficulty people have comprehending abstract statistical information, and deceptive 
qualifying language practically guarantees a failure to educate women about life 
threatening risks associated with OC. These inserts need simplified text and statistics that 
do more than just fulfill legal obligations. They also need to fulfill their obligation to the 
patient taking the medication to understand her risks.  
Dickinson, et al. demonstrated the benefits of consumer testing for medicine 
leaflets in their 2001 study and found that “leaflets with the appropriate tone, length, and 
design can do much to aid responsible medicine-taking.” Exhaustive testing is required of 
pill manufacturers before a medication can be prescribed to the public, but very little, if 




have shown that the wording currently recommended… for conveying risk information is 
consistently and significantly misinterpreted by users” (Berry 307).  
Additionally, pill manufacturers could include the results of both their studies and 
independent studies in the information provided with the prescription. Since, as Drife 
points out “studies funded by manufacturers of oral contraceptive pills produce more 
favorable results than independent studies” (898). 
“Framing information in a way that is most readily understood by the human 
mind is a first step toward educating doctors and patients in risk literacy” (Gigerenzer 
58). Women would benefit from pharmaceutical companies updating the information that 
is distributed with their oral contraceptives to include: more details about clotting 
disorders, especially that women may have them and not know; simplified text that is 
targeted to the reader; information that has undergone usability testing for clarity.  
As far as the advertising of birth control pills, marketers have an obligation to 
their clients, the pharmaceutical industries, to make the product appealing. Unfortunately 
for consumers, this means promoting the benefits while downplaying the side effects. 
This speaks to the ethics, or lack of ethics, of pharmaceutical advertising. Short of 
prohibiting all pharmaceutical advertising, it is difficult to say how these advertisements 
can be improved, and still benefit the companies paying for them. An accurate and fair 
representation of the medication’s benefits and side effects is the obvious solution. 
However, both accurate and fair are subjective, especially under the eyes of 
discriminating legal teams. Nevertheless, the over 10,000% increase in spending on these 
advertisements, an expense no doubt passed on to millions who rely on these 




HEALTH CARE PROVIDER/ PATIENT RESPONSIBILITY 
  Increasing the awareness of the dangers of thrombophilia combined with OC use 
involves more than just pharmaceutical company. There are steps that healthcare 
providers and their patients can take to improve their understanding of the risks of oral 
contraceptives. If communication can be improved on both sides of the doctor/patient 
relationship, it is conceivable that clot symptoms will be recognized for the danger that 
they are and treatment can be administered swiftly. 
“Unlike many life-threatening conditions, deep vein thrombosis (DVT) and 
pulmonary embolism (PE) can strike silently: 80% of DVT and PE occur without 
symptoms initially. As a result, some clinicians regard DVT and PE as rare” (Church). 
Unfortunately, blood clots are far from rare. “Venous thromboembolism is a major 
medical problem, affecting 1 in 1000 individuals annually, and most physicians come in 
contact with patients suffering from the disease regardless of their clinical specialty” 
(Dahlback 19). Despite the prevalence of blood clots both healthcare providers and 
patients continually miss the warning signs.  
 Fletcher et al. suggest that “preceding OC prescriptions women need to be 
informed of the potential benefits and risks… healthcare providers should provide users 
with OC information and periodically review the procedural practices during the duration 
they consume the pill” (233). Only a little more than half of the women surveyed reported 
that their doctor discussed the risks of taking birth control pills with them. And more 
alarmingly, only one woman could accurately identify which risks were actually related 




Over 80% of the women surveyed did not know about inherited thrombophilia 
before taking birth control pills. Women should be systematically informed that it is 
possible for them to have a clotting disorder without realizing, that is with no prior 
history of clots and no family history of clots. They should also be given the option to 
have a blood test to determine whether they are at an increased risk of blood clots when 
taking oral contraceptives, or in any other increased risk situation (long flights, 
pregnancy, surgery, bed rest, etc.).  
In addition to informing women of the risks associated with oral contraceptive 
use, healthcare providers need to make sure they emphasize the symptoms of these side 
effects, especially blood clots. Over 80% of the participants in this study did not know or 
were not sure they knew the symptoms of blood clot. If a patient cannot identify the 
symptoms, it is unlikely that they will take appropriate action to seek treatment.  
In the Bryden and Fletcher study about the knowledge of university-aged women 
about the benefits and risks of birth control pills, they mention the acronym ACHES as a 
list of warning signs. ACHES stand for Abdominal pain, Chest pain, Headaches, 
Eye/vision changes, Severe leg cramps. These are some of the main symptoms of blood 
clots and according to their study, 69% of the women were able to identify the correct 
terms for this mnemonic device. It is not known where this acronym originated, but the 
Bryden and Fletcher study was conducted in Canada. Based on the survey responses in 
this study, women here in the United States are not familiar ACHES. This device could 
be a powerful tool for health care providers to help educate patients about the symptoms 




Healthcare providers also should provide women with an action plan in the event 
that they experience any side effects- something more substantial than the directive 
provided with the prescription of “notify your healthcare provider if you notice any 
unusual physical disturbances.” 
Furthermore, even if patients decline the blood test assessing their risk, the very 
act of offering and declining the test will increase awareness of the side effects of birth 
control pills. Then these women might more readily recognize the symptoms of a blood 
clot and seek treatment more quickly. And if informing patients of inherited 
thrombophilia was standard protocol before prescribing oral contraceptives, healthcare 
providers would also become more aware of the possibility of blood clots in young 
women. This increased awareness could result in a quicker response when a patient 
presents with these symptoms and quite possibly the difference between life and death.  
 Moreover, physicians need to discuss all contraceptive options with women, even 
if they request a prescription for birth control pills, as over half the women surveyed did. 
More than 60% of the participants reported that their doctor’s did not discuss any other 
options with them. In fact, in the comment section, many women chose to point out how 
readily their doctors prescribed birth control pills: 
• I think they’re too often the first option doctors prescribe for reasons other than 
birth control. That’s frustrating. They’re not a magic pill and some doctors seem 
to think they are. 
 
• Doctors are much too quick to prescribe and dismiss the side effects or even give 





• Every other doctor I had acted like it was giving out Altoids, and I always looked 
at it that way myself as a result- until meeting a new doctor. 
 
And from one survey participant who chose to send an email after taking the survey: 
• The pill is given out like candy, and women are suffering the results (abnormal 
paps and cervical cancers scares before age 22 for myself and my sister, long 
term risks of breast cancer, on and on). 
 
As far as health care provider and patient responsibility, Edwards et al. point out 
in a recent article in Patient Education and Counseling that risk communication is 
becoming increasingly more important in the health care. According to the article, risk 
communication can be defined as “the open two-way exchange of information and 
opinion about risk, leading to better understanding and better (clinical) decisions” (4). In 
addition to the healthcare provider’s responsibility to inform patients of risks associated 
with oral contraceptive use, patients need to take a greater role in their own healthcare. 
Edwards et al. also suggest that the healthcare industry is experiencing a shift 
“from the paternalistic paradigm towards one of greater patient participation and 
responsibility” (4). With advances in medicine occurring daily, it is impossible for one 
doctor to have the most up to date information on all conditions and treatments. And in 
this information age women, especially young women who are seeing doctors for the first 
time without a parent, need to take responsibility for their own health.  It is the 
responsibility of both the patient and the doctor to ensure the best health care possible is 
provided.  
Obviously this patient/ healthcare provider relationship is an ideal to strive 




healthcare providers need to be addressed. However, women can take steps to increase 
their quality of care by researching their complete family medical history, reading all 
materials that accompany their medication, and keeping abreast of pertinent innovations 
in medicine. 
 
TESTING FOR THROMBOPHILIA 
 “In 2001 a consensus statement from the American College of Medical Genetics 
recommended against screening for factor V Leiden in asymptomatic women 
contemplating the use of oral contraceptives unless they have a personal or family history 
of thromboembolism or other risk factors” (Drife 899). The reasoning behind this 
standard of care is several cost analysis studies that have meticulously broken the 
argument down into statistics of the cost to prevent one death.  
“Although the laboratory cost of screening for factor V Leiden has reduced 
considerably over the past few years, as screening technology has improved and become 
more widespread, the cost of seeing patients, obtaining samples from them and 
subsequently counseling them, means that each patient screened would cost a minimum 
of £15 and perhaps more realistically £25 at 1999 costs.” (Walker 11). With inflation 
accounted for at 2% a year, the cost today would be approximately £17 to £30 or $25 to 
$43.  
Unfortunately for Americans, according to Greenwood Genetic Center, in 
Greenwood, South Carolina, a test for factor V Leiden currently costs approximately 
$150. The scope of this study does not cover why medical care here in the United States 




it is possible to screen for much less than $150, and if screening rates were to increase, 
the cost of the tests would likely decrease. Furthermore, a recent study in Spain has 
devised a “rapid, reproducible, cost-effective, and simple method… to simultaneously 
detect carriers of thrombotic genetic risk factors” (Lopez et al. 349). This test removes 
the manual aspects of the screening process that can increase the cost and the possibility 
of erroneous test results. And unlike previous automated tests, which can test for only one 
mutation (i.e. the test from Greenwood Genetic Center that tested only for FVL), this 
new, inexpensive, and automated test is able to detect multiple mutations in human DNA 
samples. (Lopez et al. 354). 
Only 7% of the women surveyed in this study would not be willing to take a 
blood test to assess their risk for blood clots. And more than 33% of the women surveyed 
for this study would be willing to pay these costs out of pocket. Moreover, if the test 
costs were closer to $20, an additional 30% would be willing to pay. If women are 
willing to pay for the test, how can it not be cost effective to screen them? 
Another thing these “cost effective” analyses fail to take into account is the cost 
of hospital stays, treatment, and medication for those women who have clots and live, but 
often need a lifetime of treatment (like myself). Not to mention the huge burden, financial 
as well as emotional, of the countless miscarriages and stillbirths. Do the lives of unborn 
babies not count in a cost per preventable death study? 
“Of all patient groups evaluated, universal screening of women prior to 
prescribing hormone replacement therapy was the most cost-effective” (Wu, et al. 131). 
However, the majority of women that would be screened for hormone replacement 




they had been screened, or at least been given the option to be screened, at the time they 
were prescribed birth control pills, they would already understand their risk for 
developing a clot.  
Many of these studies propose, in lieu of testing all women, that patients should 
be screened for a family history and that those with a legacy of blood clots could then be 
tested. In an article in Fertility and Sterility, Dr. Mitchell Crenin and colleagues claim 
that “the best screening tool we have is taking a thorough personal and family history 
related to venous thromboembolic events” (650). Though 85% of the women surveyed 
for this study said they were asked about their family histories, only about half of those 
actually discussed it with their doctor. And the Fletcher et al. study only found that 61% 
of women reported receiving a family history review, with 14% unable to recall what 
information was included in the review (231).   
Furthermore, family history has not been proven to be an effective screening tool. 
In a study published in Thrombosis and Haemostasis, Schambeck et al. found that fewer 
than half of the women with FVL would be discovered if family history were the only 
basis for screening. They conclude that “many FV Leiden carriers would escape the 
physician’s notice if one just relies on the family history of the patient” and that “family 
history is an unreliable criterion to detect FVL carriers” (1480, 1482). Another study by 
Cosmi et al. concurred, adding “family history of venous thromboembolism has an 
unsatisfactory sensitivity… a policy of selective screening may therefore miss a 
substantial number of women at increased risk of thromboembolism when taking oral 




Indeed, my family history shows only a grandmother that had a stroke in her 60s, 
something easily explained by her age and the fact that she smoked. And one of the 
survey participants had a similar experience that she described: 
I experienced bilateral pulmonary embolisms when I was taking birth control 
pills. It turned out that I had factor V Leiden (homozygous), but my family was 
unaware of our genetic condition until I had my clots. I can't remember my doctor 
ever discussing blood clot risks with me when prescribing BCPs. My grandfather 
had had a stroke, but I don't recall discussing that. 
 
Another researcher recommends testing for FVL only if there is another 
permanent or short-lasting risk for VTE (Spannagl 111). Other risk factors that should be 
taken into account are continually being explored. For example, recent studies have 
shown that migraines, particularly those with auras, or visual disturbances, are a risk 
factor for stroke, this risk further increased with the use of OC. As previously mentioned, 
the connection between migraines and strokes is extensive enough that the World Health 
Organization recommends that women suffering from migraine with aura should never 
use birth control pills (Allais et al. S12).  
A further study by Bassi et al. has shown that 62.5% of patients who suffer 
migraines carried at least three thrombophilic factors including FVL. Their findings 
indicate that “in order to assess prevention strategies, it could be appropriate to perform a 
complete screening in young patients suffering from migraine” (138). It is also my 
experience that this could be a predictive factor for thrombophilia. Though I have no 
personal history of migraine, aside from the episode that preceded my stroke, both my 




participant who reported having pulmonary embolisms as previously quoted, mentioned 
having a history of migraines: 
I originally took Ortho Tri-cyclen, but the doctor (at the student health clinic) 
switched me to Mircette to help with migraines. It turns out this is one of the types 
of BCPs that causes the greatest risk for clots. 
 
“Paying attention to risk factors has dramatically reduced the incidence of fatal 
thromboembolism after caesarean section in the UK and the same approach could be 
applied to thromboembolism and oral contraceptives” (Drife 899). According to the 
British National Formulary, birth control pills should be avoided if women are obese 
(Drife 899). However, in the United States, there is no similar restriction, despite ranking 
as the 9th fattest country in the world (Great Britain ranked 28th) by the World Health 
Organization (Streib). Dr. James Trussell explains the danger in Contraceptive 
Technology Update, “While much attention has been focused on OC failure in obese 
women, clinicians should look at the risk of deep vein thrombosis (DVT) in this 
population. Obesity is a risk factor for venous thromboembolism, and OCs further 
increase the effect of obesity on DVTs” (90). 
Another concern regarding systematically testing for thrombophilia is that it “may 
not significantly reduce the incidence of VTE… as the incidence of unplanned 
pregnancies is likely to increase” (Walker 13). However, just because a woman is advised 
against taking birth control pills, does not mean she is incapable of using other types of 
contraception. Intrauterine devices (IUD) and barrier methods are both safe alternatives, 
and the IUD has been shown to be statistically more effective than most hormonal 




FVL can be worthwhile even if the advantages of oral contraception are higher assessed 
than the thrombotic risk. Affected women knowing about their additional risk could 
contribute to the prevention of thrombosis in risk situations” (1480). 
 Perhaps doctors Nina Caplin and Laurie Edelman put it best, in their response in 
The New England Journal of Medicine to an article that suggested women should not be 
routinely tested for thrombophilia because it “would deny contraceptives to about 5 to 10 
percent of white women… while preventing very few fatal thromboembolisms.” They 
said: 
This is not acceptable. No woman should die unnecessarily from complications of 
contraceptive use, nor should any woman be subjected to a possible stroke, 
pulmonary embolism, or deep venous thrombosis when the occurrence of these 
complications could have possibly been prevented by a simple and accurate blood 
test. Other acceptable forms of birth control are available. Not offering women an 
informed choice and thus perhaps significantly increasing their risk of a 
preventable complication associated with substantial morbidity should not be the 
standard of care.  
 
 While testing every woman for thrombophilia may still be a debatable practice, 
this research has shown that most women would be willing to pay for that information 
about their health. Furthermore, new tests are being created that decrease the cost and 
error associated with these test. And though she is only one example, the woman 
surveyed who answered that she knew about clotting disorders because she is “from a 
family of Drs, so got tested before I began taking the pills,” brings up a good point. If 
doctors find inherited thrombophilia enough of a risk to test their family members before 




For most health care providers who are reluctant to incorporate thrombophilia 
testing into their practice, this research provides some illuminating information to 
consider. Family history is not an accurate tool to identify women with inherited 
thrombophilias, however a family history of migraines may prove to be an indicator of 
increased risk of thrombosis. Additionally, clinicians should consider recommending 






















CONCLUSIONS AND LIMITATIONS 
 Overall this study found that women who use oral contraceptives are not aware of 
inherited thrombophilia. And like previous research, this study showed that most of those 
women do not fully understand the risks of taking birth control pills, including their 
personal risk for blood clots that would be increased if they have a clotting disorder. But 
perhaps most alarming is that the majority of these women do not even know the 
symptoms of a blood clot, and would therefore not recognize if they had one, or know to 
seek treatment immediately.  
 Additionally, this study confirms the lack of information available to women 
about clotting disorders. This information is not found in advertisements for birth control 
pills, on non- profit websites about birth control pills and their risks, or on literature 
provided with the prescriptions. It should come as no surprise that women are not aware 
of something so infrequently and inadequately mentioned.  
 The amount of conflicting information available to women, physicians, and 
researchers alike, makes it difficult to determine where the breakdown in communication 
occurs. Clearly, women need more information from their health care providers, however 
these health care providers need comprehensible and accurate information from 
pharmaceutical companies. And pharmaceutical companies need take responsibility for 
making their risk information for birth control pills as easily understandable as their 
selling points. As mentioned in the results section, many survey participants were 





I’ve had two different GYNs give me completely contradictory information about 
side effects from BCPs… Overall, I’m surprised at how little doctors seem to 
know about female BCP- I haven’t experienced this amount of ambiguity with any 
other medical specialty or problem.  
 
This study also made clear that women are eager to have a voice in the on-going 
dialogue about birth control pills. Even if their issues with oral contraceptive are not 
related to cardiovascular risks, women still have strong feelings about taking these 
hormones. Based on the concerns voiced by the women surveyed, it appears that more 
research should be conducted on birth control pills, their risks, and long and short-term 
side effects. And this investigation has shown, even more than anticipated, the desperate 
need for increased awareness of thrombophilia for women. 
In spite of this compelling evidence, this study does have limitations. For 
example, because the survey participants were recruited online through networking, it is 
possible that some may have been aware of my experience and therefore were biased in 
their responses. This was countered by qualifying the question about knowledge of 
clotting disorders with the option of knowing about clotting disorders but not being aware 
of them when they first began taking OC. Ideally, participants with no prior knowledge of 
the researcher would be have been randomly selected for the survey. However, time 
constraints required this study to be conducted with the convenience sample available. 
Also, to provide the most anonymity possible for participants, they were not 
requested to provide information on their educational background, race, or 
socioeconomic status. This limits the demographic information available. Because the 




or Facebook. It is therefore reasonable to conclude that participants were fairly educated 
and reasonably well-off. 
This study was also limited by a lack of published research on this topic in the 
United States. The majority of the articles cited in this thesis were studies done in Europe 
or Canada. Though it is unlikely that results for most of these studies would be different 
had they been conducted in the United States, it cannot be concluded that all of the 
information can be transferred. It is unfortunate and disconcerting that comparable 
studies done in United States could not be found. But perhaps this is not surprising given 
that by 1988 surveys showed “that birth control has disappeared from the list of medical 
research's 35 top priorities” (“Timeline: The Pill”).  
That said, the object of this study was not to vilify oral contraceptives or to deny 
them to any woman looking for effective means of contraception. Certainly oral 
contraceptives are of considerable benefit to many woman in the United States and 
perhaps even more so in developing countries, where the risk of maternal death is much 
greater than the risks involved with taking oral contraceptives   
 However, the benefits of oral contraceptives do not always outweigh the risks, 
particularly in women with clotting disorders. Now that more accurate and cost effective 
tests for clotting disorders have been identified, testing should be considered especially in 
women who have additional risk factors that have been identified. Additionally, since this 
research shows that most women would be willing to take the test, and even pay for it, 
testing should be made available to them, as well as information about clotting disorders.  
While there will always be extraordinary situations, with the amount of existing 




embolisms, DVTs, multiple miscarriages, and still births because they have an 
undiagnosed clotting disorder. As the Surgeon General pointed out, blood clots are 
preventable. By making women aware of inherited thrombophilia, the risks involved with 
taking hormones, and the symptoms of thrombosis, we can reduce the instance and 
























 After I got out of the hospital, I was referred to a hematologist who diagnosed me 
with Factor V Leiden. When my test came back as “only” heterozygous, he treated my 
situation like it was, for lack of a better phrase, no big deal. This left me frustrated and 
confused. If my clotting disorder was no big deal, then why did it nearly kill me?  
I wanted to know why no one had ever told me about the existence- or my chance 
of ever having- clotting disorders. I wanted to know why doctors had prescribed me birth 
control pills without informing me about the side effects or offering me any other 
options. I wanted to know why when I researched my symptoms online, the only 
information I could find indicated that I had a migraine. And most importantly, I wanted 
to know why over the course of a week, four physicians, including an OB-GYN, a 
physician at an urgent care clinic, and two different emergency room doctors, did not 
even consider that I might have a blood clot, despite being on birth control pills and 
presenting with symptoms of a stroke- and in the case of the OB-GYN office, a DVT (an 
unexplainable pain in my thigh). 
These questions were the impetus for this research study. Obviously my bias has 
formed this work, perhaps in ways that I cannot even realize. But my passion for the 
subject also motivated me to keep researching when many articles concluded that FVL 
was not prevalent enough or dangerous enough to warrant testing. While the scope of this 
research does not cover all of the issues that accompany systematic testing of women 
prior to prescribing birth control pills, I believe it demonstrates that a simple cost-per-




on FVL, this study incorporates a point of view that is so often missing in a much of 
medical research: that of the patient. 
 
Not long after I was discharged from the hospital, I had an allergic reaction to my 
anti-seizure medicine. I returned to the emergency room at the request of my neurologist. 
This time they immediately took me to an examination room. When the doctor walked in, 
the same doctor who had finally diagnosed my stroke, he impressed upon me the gravity 
of my situation and of this issue when he said to me, “I’m so glad to see you. I didn’t 




















































































































IRB CONSENT AND APPROVAL 
 
 
Consent Form for Participation in a Research Study 
Clemson University 
 
Birth Control Pill Survey 
 
Description of the research and your participation 
 
You are invited to participate in a research study conducted by Kerry Gomer, under the 
direction of Dr. Sean Williams. The purpose of this research is to understand more about 
birth control pills. 
 
Your participation will involve taking an online survey. 
The amount of time required for your participation will be 5-10 minutes. 
 
Risks and discomforts 
 




There are no known benefits to you that would result from your participation in this 
research. This research may help us to understand how women obtain information about 
birth control pills. 
 
Protection of confidentiality 
 
Participants taking this survey will remain anonymous.  
 
In rare cases, a research study will be evaluated by an oversight agency, such as the 
Clemson University Institutional Review Board or the federal Office for Human 
Research Protections, that would require that we share the information we collect from 
you. If this happens, the information would only be used to determine if we conducted 




Your participation in this research study is voluntary. You may choose not to participate 
and you may withdraw your consent to participate at any time. You will not be penalized 




If you have any questions or concerns about this study or if any problems arise, please 
contact Dr. Sean Williams at Clemson University at 864-656-2156. If you have any 
questions or concerns about your rights as a research participant, please contact the 





From: Rebecca Alley  
Sent: Thursday, February 05, 2009 9:41 AM 
To: Sean Williams 
Subject: Validation of IRB protocol # IRB2009-031, entitled “Birth Control Pills: Communicating the 
Risks” 
 Dear Dr. Williams, 
 The Chair of the Clemson University Institutional Review Board (IRB) validated the 
protocol identified above using Exempt review procedures and a determination was made 
on February 5, 2009, that the proposed activities involving human participants qualify as 
Exempt from continuing review under Category B2, based on the Federal Regulations 
(45 CFR 46).  You may begin this study. 
 Please remember that no change in this research protocol can be initiated without prior 
review by the IRB.  Any unanticipated problems involving risks to subjects, 
complications, and/or any adverse events must be reported to the Office of Research 
Compliance (ORC) immediately.  You are requested to notify the ORC when your study 
is completed or terminated. 
 Attached are documents developed by Clemson University regarding the responsibilities 
of Principal Investigators and Research Team Members.  Please be sure these are 
distributed to all appropriate parties. 
 Good luck with your study and please feel free to contact us if you have any questions.  
Please use the IRB number and title in all communications regarding this study. 
Sincerely, 
 Rebecca L. Alley, J.D. 
IRB Coordinator 
Office of Research Compliance 
Clemson University 
223 Brackett Hall 
Clemson, SC  29634-5704 



















































These survey results represent the raw data that was collected before“Other (please 
specify)” responses were coded. The results in the manuscript represent these results 















































































RESPONSES TO QUESTION 24 
“Please share anything else about your experience taking birth control pills:” 
    Comment Text Response Date 
  1. Sometimes hard to remember to take them every 
day. 
 Wed, 2/18/09 9:17 PM  
  2. I have has issues with it not wanting to work after 
3 to 6 months of use. At one point last year with 
being on the pills i was getting double periods. 
Which made mt OB put me on the ring and still 
having a few issues with that. None other than he 
wanted me to use it continuous for three months 
issuing a new ring every month and on the third 
month have your cycle and then start over, well I 
have only made it to two months... But at least I 
am not having to cycles a month! 
 Wed, 2/18/09 6:31 PM  
  3. It regulated my menstrual problems well. I didn't 
expect it, but I felt emotionally happier. Yet my 
closest friends and family complained that I was 
acting very strange and depressed. This is why I 
quite taking the pill. 
 Wed, 2/18/09 4:57 PM  
  4. I think it is not considered a big deal by the 
medical community. I wondered after being on the 
pill so long if there were any affects, but have had 
difficulty getting doctors to even discuss this. 
 Wed, 2/18/09 3:40 PM  
  5. I am currently not taking birth control pills in 
order save some money on prescription 
medications. I have stopped taking all nonessential 
prescription and OTC medications. I may take 
generic birth control pills again in the near future 
but before I do I may research a bit on this blood 
clot issue. 
 Wed, 2/18/09 2:15 PM  
  6. I was young (18). I smoked. I developed veins in 
my legs. I feel this is due to the combo of smoking 
and taking bc pills 
 Wed, 2/18/09 6:25 AM  
  7. I didn't know that it will enlarge the cysts i 
currenly have in my breast. 
 Tue, 2/17/09 8:33 PM  
  8. It has taken me a long time to find a pill that works 
well with my body - I suffered from nausea on a 
daily basis. 




  9. severe mood swings  Mon, 2/16/09 8:51 PM  
  10. I developed a blood clot. My PCP would not 
perform a test to understand why the blood clot 
happened. He said that if I were planning to have 
children, I should have the test and figure out why 
the clot happened, but would not recommend it 
otherwise (reason: I would worry needlessly). 
After I had the clot, I stopped taking the pill and 
had an IUD implanted. I have not (to my 
knowledge) had any problems since. 
 Mon, 2/16/09 5:37 PM  
  11. You should ask a question about whether the pills 
were prescribed in the first place. Usually they are, 
but in some cases, you may get them another way. 
Its not the way things are supposed to be done, but 
it happens. 
 Mon, 2/16/09 1:43 PM  
  12. I'll start by saying that I am a normal, healthy 25 
year-old women. I eat a healthy diet low in refined 
carbohydrates and saturated fats, and I work out 5-
6 days per week. All things aside, my health is 
always a concern b/c of my experience on birth 
control pills. My experience on birth control pills, 
the Nuvaring, or Depo-Provera all proved to be 
horrendous. I stopped having periods, developed 
crappy symptoms, gained weight, and eventually 
was diagnosed with Polycystic Ovarian Syndrome 
(PCOS) in 2007. I stopped taking birth control that 
year and went through a series of naturopathic 
supplements in order to regain my normal 
menstrual function. It has taken me over a year to 
begin having cycles again. I think birth control 
came straight from hell and I hate, hate, hate it. I 
would rather undergo chinese water torture daily 
than take birth control, and that is the God's honest 
truth. I think doctors and pharmaceutical 
companies owe it to patients to be more forthright 
about the risks women are taking on by messing 
with their body's natural rhythms like that. It may 
work for some women, but I know a great many 
women who have developed lifelong issues as a 
result or in part due to taking the faux hormones in 
birth control pills, shots, or rings. It's really sad, 
but life is not some stupid Loretta Lynn song 
about "I've got the pill." The pill doesn't solve 
every problem, and for me, it created a great many 
additional problems. My fertility has been affected 




forever by my under informed choice to go on 
birth control, and by the irresponsible doctors who 
encouraged me to switch methods rapidly "until I 
found what worked for me." Nothing worked - the 
reason being because my body doesn't handle birth 
control well. It makes me suicidal, angry, bloated, 
moody, and just miserable - every. single. day. 
Like I said...I'd just as soon go under some form of 
Guantanamo-level torture before I'd ever, ever, 
ever, ever, EVER go on birth control again. If and 
when my husband and I have kids of our own (I 
say IF because with my PCOS, my fertility has 
been so affected that we may never be able to 
concieve our own children, sadly...thanks, birth 
control!) and we decide we're done having 
children, he's agreed to get a vasectomy (since I've 
been through enough already, he says). 
  13. I've never had a problem...they have been very 
effective in treating my period problems (heavy 
bleeding, intense cramping) and in dealing with 
acne. I stopped taking them in order to get 
pregnant and plan to start back as soon as I have 
the baby and am done breast feeding. 
 Sat, 2/14/09 9:07 PM  
  14. The hormones in the pill caused drastic mood 
swings that eventually prompted me to stop taking 
the pill. 
 Sat, 2/14/09 10:27 AM  
  15. Never had a problem.  Fri, 2/13/09 11:38 PM  
  16. I am glad to have other options now that I am 
older and have children. 
 Fri, 2/13/09 7:26 PM  
  17. I stopped taking birth control pills because I didn't 
like the feeling of having chemically regulated 
hormones. Thus, my current birth control is non-
hormonal. 
 Fri, 2/13/09 2:08 PM  
  18. It was never explained why the particular 
prescription I was given was chosen over other 
available options/options were not described or 
discussed 
 Fri, 2/13/09 1:28 PM  
  19. They give me mood swings that are more severe 
than when not taking them. 
 Fri, 2/13/09 12:16 PM  
  20. very positive experience  Fri, 2/13/09 11:05 AM  
  21. I would be interested in learning about the number 
of women who have had miscarriages and the 




corrleation with birth control and the length of 
time birth control was taken. THere may be no 
correlation, but the number of women who are 
having miscarriages is alarming. 
  22. I stopped them because they made me moody. I 
will not take birth control anymore because I know 
it increases risk of breast cancer. I think my 
gynecologist (and GYNs in general) are biased 
toward giving birth control to people despite the 
risks. My current gynecologist completely 
downplayed any risks associated with hormonally-
based birth control, so I do not trust her (or most 
doctors for that matter). 
 Fri, 2/13/09 9:29 AM  
  23. Also was on the Ortho Evra Patch for a time...this 
proved to be a bigger clotting risk that ORAL 
contraceptives and worth your time in reading 
about. 
 Fri, 2/13/09 6:51 AM  
  24. I've been really happy with the pill I've been on for 
years and years. I sometimes wonder if it will 
effect me having kids or any other negative 
effects, but I guess I'll find out later. So far, it's 
been great and I'm very happy. 
 Thu, 2/12/09 10:55 PM 
  25. Through a college health center my birth control 
brand was changed numerous times due to change 
in insurance policy. The pharmacist assured me 
they were all the same, some were just generic. I 
was not told of any changes in hormone dosage. 
They changed the brand at least three or four times 
in only a few months. During that time I 
experienced extreme mood swings, depression, 
and anger. My mood would change so drastically I 
considered seeing a therapist because I was 
concerned I had a chemical imbalance. I went to 
the same college health center for an annual pap 
smear and told the nurse practitioner about the 
changes in birth control brands and my extreme 
changes in mood. She had to check on the 
database to see exactly what they kept changing. 
When she saw the hormone differences in 
prescriptions she actually gasped. Apparently the 
changes in brand of birth control did NOT have 
the same hormone level despite what the 
pharmacist told me. She then prescribed me a 
brand that was low in hormone levels and on my 




insurance plan. My moods are not as crazy as they 
once were. This was an extremely draining time in 
my life when they kept changing the prescription. 
I can't say it was due to the birth control but I 
honestly think it was. 
  26. I am not currently on birth control pills. I do not 
think that the risks are worth it. 
 Thu, 2/12/09 10:13 PM 
  27. Taking a pill on a daily basis was difficult so I 
switched to the birth control patch, which I am 
currently using. 
 Thu, 2/12/09 9:26 PM  
  28. I started taking Yaz to induce menstration at age 
22. I began menstruating fairly normally for a few 
months and then bled excessively for 30 
consequetive days. One of the side effects of note 
in my case was breast enlargement. It was such a 
drastic change that people thought I had 
undergone breast enlargement surgery. After 
bleeding so much, my gynecologist changed me to 
the Ortho-evra patch. I did faily well on this, 
however my mood changed a lot. In the end, my 
husband and I decided that birth control was not 
for us. 
 Thu, 2/12/09 7:20 PM  
  29. I think there is still confusion about whether it's a 
good idea to take BC pills when you know you 
want to try to become pregnant in a few 
months...how long a woman should be off the pill 
is still inconsistent among doctors. Also, at what 
point can perimenopausal woman stop taking the 
pill? I don't see these issues addressed well 
publicly. 
 Thu, 2/12/09 4:14 PM  
  30. Due to thyroid problems (I assume), I can only 
take pills that are consistent dosages throughout 
the month, which I did not realize until I tried ones 
that didn't' work when I was 17. Also, I was put on 
the pill at 11 because my thyroid problem was 
undiagnosed. 
 Thu, 2/12/09 3:47 PM  
  31. emotional roller-coaster, weight gain, very 
irritable 
 Thu, 2/12/09 3:32 PM  
  32. I was miserable. I never knew there were options 
for the strength of hormones in the pills. I stopped 
taking them because I was sick and because I 
learned of two friends who had strokes after taking 
a form of BC. 




  33. When I went off the pill, I realized how much they 
affected my personality. Everyone discusses how 
they ease PMS symptoms and etc., but after going 
off the pill I was much more relaxed, my husband 
and I fought less and my periods were actually 
lighter. Also, in contrast to the tale that you lose 
weight when going off the pill, I gained 5-7 lbs, 
quickly. Since i had been on the pill for such a 
long period of time, almost 20 years, I always 
believed my periods were heavy when, in fact, 
they are quiet light. I will never go back on the 
pill. Doctors are much to quick to prescribe and 
dismiss side effects or even give any credit to 
some of the emotional effects I felt the pill caused, 
such as, irritability, short temper--much these 
negative emotions disappeared after I ceased 
taking the pill. 
 Thu, 2/12/09 1:28 PM  
  34. I think the experience taught me to take 
responsibility for myself. My dad is the one who 
actually wanted me to start taking them and even 
though I was 16, it was a great choice. I am 25 and 
have never had a pregnancy scare, which is good 
for me because I am not ready for children right 
now. 
 Thu, 2/12/09 12:55 PM 
  35. had no problems  Thu, 2/12/09 12:16 PM 
  36. I am 44 & have taken the lowest dose of BCP for 
28 years. I'd rather not take them, but fear 
problems if I stop after all this time, and fear a 
pregnancy. 
 Thu, 2/12/09 11:31 AM 
  37. Due to the estrogen in the birth control pills they 
are not a good option for anone with bi-polar or 
similar emotional imbalances, I wish they would 
make a pill that worked without the hormones 
 Thu, 2/12/09 10:49 AM 
  38. I was shocked- and grateful- when I finally found 
a doctor who discussed alternatives with me, 
suggested a wide variety of reading, and let me 
then do my research and make my own decision 
before wiring a prescription. After doing the 
reading, there is no way I will ever take another 
birth control pill in my life. Every other doctor I 
had acted like it was giving out Altoids, and I 
always looked at it that way myself as a result- 
until meeting a new doctor. 




  39. I've had two different GYNs give me completely 
contradictory information about the side effects 
and dangers of BCPs. (My discussions were 
related to problems with a friable cervix.) Overall, 
I'm surprised at how little doctors seem to know 
about female BCP - I haven't experienced this 
amount of ambiguity with any other medical 
specialty or problem. 
 Wed, 2/11/09 11:45 PM 
  40. Birth control pills have changed significantly since 
I have taken them. Also, public knowlege has 
changed significantly. Years ago, physicians were 
only mildly concerned with finding the appropriate 
dosage for each patient. Now there seems to be 
more interest in finding the right pill for each 
patient, if possible. While my length of time taking 
the pills extends from 1971-1982, I had three full 
term pregnancies during that time, so my exposure 
was less than someone who has taken birth control 
pills for an extended period of time with no 
breaks. I am sure that if I were to be prescribed 
birth control pills today, I would be much more 
skeptical and wary about taking them at all. Being 
post-menopausal, I am only glad that I did not take 
hormone replacement therapy 10 years ago when 
it was first prescribed for me. At that time, it was 
the standard, more or less with most physicians 
advocating HRT as beneficial to women to prevent 
heart disease. I was not comfortable with that and 
then, 2 years later, new studies were published 
showing that HRT is not even a good idea in most 
instances. Everyone needs to be their own best 
advocate whether is is birth control pills, or blood 
pressure medicine. Doctors usually follow the 
"tide" of current thinking and they are not always 
correct. 
 Wed, 2/11/09 9:46 PM  
  41. I had virtually no symptoms other than a 
regulated, expected period. I switched to a few 
different pills over the 13 years I took them. When 
I started taking them, my migraine headaches 
stopped. 
 Wed, 2/11/09 9:43 PM  
  42. I started taking them over 20 years ago and 
stopped to get pregnant after 5 years, so some of 
my memories about the information I got are 
sketchy. I alos think the information on risks has 
changed some in the past 20 years and I have not 




paid as much attention since I no longer take 
anything. 
  43. Originally started taking pills to decrease 
menstrual cramps- helped a LOT (and still does); 
now, main benefit is birth control. 
 Wed, 2/11/09 8:45 PM  
  44. I was too young and too absent minded when I 
took the pill. I never took them consistently, so I 
finally just stopped. 
 Wed, 2/11/09 8:43 PM  
  45. Over time it began to cause sever mood swings, 
and irrational emotional symptoms. I also believe 
it can be a cause of breast cancer. After eight years 
I have stopped taking them. I would recommend 
other forms of contraceptives to friends/family 
besides the pill. 
 Wed, 2/11/09 8:36 PM  
  46. I think they're too often the first option doctors 
prescribe for reasons other than birth control. 
That's frustrating. They're not a magic pill and 
some doctors seem to think they are. 
 Wed, 2/11/09 8:35 PM  
  47. It caused my post partum depression...I had been 
taking the same pill for 10 years and after my 3rd 
child it caused the hormonal imbalance and it 
caused hte depression I had to go off of it and 2 
days later it was fine. I had never heard that 
before... 
 Wed, 2/11/09 7:46 PM  
  48. Only took the pill for a couple of years and that 
was about 30 years ago. Thankfully, I don't have 
that to worry about any more! 
 Wed, 2/11/09 7:45 PM  
  49. I liked being on BCPs for the amenorrhea but I did 
worry about my health once I reached age 35 (and 
before) which lead me to discontinue use at age 
38. I know there are lots of associated risks (as 
with ANY medication) but, at the time, the benefit 
outweighed the risk. However, I become more 
informed as I got older and because of my 
profession. I do not feel that my healthcare 
providers 15 years ago stressed the need to educate 
myself on the risks of taking BCPs. We discussed 
not missing pills and the risk of pregnancy, not the 
risk to my health. I was lucky during those 
uneducated years that no devastating side effects 
occurred. 
 Wed, 2/11/09 7:28 PM  
  50. It infuriates me that most insurance companies do 
not pay for BC pills anymore, but they WILL pay 




for Viagara!! I think unwanted pregnancies and 
cost of raising those children should have more 
priority! 
  51. In reference to question number seven, I have a 
family history of a genetic mutation Factor V 
Leiden that increases the risk of blood clots and 
my sister was told that she could only take certain 
types of birth control as a result of her having this 
mutation. I decided to have the test before I started 
any form of birth control. Luckily for me, I didn't 
have the mutation and this was information I 
provided to my OB-GYN when I asked for a 
prescription for birth control. 
 Wed, 2/11/09 6:21 PM  
  52. It made me so moody and irritable that I stopped 
taking it. 
 Wed, 2/11/09 6:17 PM  
  53. I experience non of the "normal" side effects, 
unless I miss a pill. 
 Wed, 2/11/09 5:48 PM  
  54. I've been on and off bc since I began in 1990 for 
different reasons not just preventative measures. 
 Wed, 2/11/09 5:12 PM  
  55. I don't understand the commercials for the nuvo-
ring whose main argument for switching is that 
you don't have time to take a pill every day. I 
mean, really? You don't have time to take ONE 
pill?? 
 Wed, 2/11/09 5:12 PM  
  56. I wasnt told herbs can interupt the pills and I have 
a Son to prove it. 
 Wed, 2/11/09 5:02 PM  
  57. i had extremely irregular periods and heavier 
bleeding. I also had a negative hormonal reaction 
 Wed, 2/11/09 5:01 PM  
  58. I really love it because I had the worst cramps and 
PMS. I am anemic and the pill really helps. Also 
knowing that if I use a second form of birth 
control I pretty much clear of getting pregnant 
while on the pill. Very reassuring. 
 Wed, 2/11/09 5:00 PM  
  59. I feel like very limited information is provided to 
women regarding how birth control pills actually 
work. The more information I found about how 
the pills worked and what some side-effects could 
be, the less comfortable I am with them. I feel 
similarly about the IUD. That being said, I believe 
that many healthcare plans continue to be sexist 
with their coverage of birth control--for example 
by allowing coverage for vasectomy and/or viagra 




but not for birth control taken by women. 
  60. I did gain some weight - about 5-7 lbs. I went off 
the pill because of headaches and because I was 
getting married and wanted kids. I don't think the 
headaches had anything to do with my pill because 
I still have the headaches and they are due to 
temperomandibular joint disorder and not 
migraines. 
 Wed, 2/11/09 4:21 PM  
  61. I've taken many different kinds over the years. I 
wish they were more clear about what types & 
amounts of things are in them (progestin, synthetic 
versions, estrogen, androgens) and what the likely 
side effects are for these specific ingredients. 
Androgens can be VERY unhealthy for lots of 
women, and for some cause hair loss (which no 
one seemed to know when I experienced this and 
told my own health care provider about it). I just 
wish there was a chart of all the BC options with 
ingredients listed and their possible effects listed. I 
don't understand why we aren't presented with that 
information and allowed to have a voice in which 
prescription we get. 
 Wed, 2/11/09 4:18 PM  
  62. The first pill I tried (YAZ) I reacted to within 48 
hours. Heart racing, mind would not stop running, 
chest tightness. A month later I tried tri-cyclen 
low. On day 11, one arm was numb, I could not 
raise my arm very high, I had no strength in the 
arm, and I could not think of common words. I 
went to Urgent Care and the physician determined 
it was highly probably due to the BC pills. I 
stopped taking them. I have gone back to a copper 
IUD. This experience occurred when I was 39 and 
I had never taken BC pills before, nor will again. I 
took them against the advice of my brother, a 
medical professional, whose friend died of a stroke 
brought on by BC pills. He definitely took the 
opportunity to remind me that he'd been right! 
 Wed, 2/11/09 4:16 PM  
  63. Even though I know the symptoms and risks 
associated with it, I still use birth control and have 
for 9 years. I will probably get off of them soon. 
 Wed, 2/11/09 4:04 PM  
  64. Health insurance coverage of specific types of BC 
pills seems to change frequently - for example, 
I've been on three different brands within the last 
year. My doctor has not told me of this switch, 




rather it is the pharmacist that has notified me of 
the change (pharmacy is a part of the larger 
medical system). Usually the notification is "we 
are changing your type of birth control pill - please 
let us know if you have any questions" rather than 
a full description of what (if anything) is different 
about the pills they are switching me to. Since one 
of the switches involved going from a tri-cyclic to 
a constant dose (without explanation of what that 
means for my particular concerns - blood pressure 
and dysmenorrhea), I was not satisfied with the 
interactions described above. 
  65. No doctor ever talked to me about lots of options 
for birth control. It was just "you want the Pill? ok, 
here you go." 
 Wed, 2/11/09 3:33 PM  
  66. I wish my doctor had told me more of the risks 
and discussed it with me more. That is why I read 
the pamphlet that came with it so carefully... After 
I had been taking BC pills for about 3 months I 
heard of a friend who had blood clots from it and 
then I re-read the pamphlet. I would LOVE it if 
there was a way for me to know how much at risk 
I am for something like blood clots. I would be 
willing to pay up to probably $250 to find out if it 
was a fairly sure thing (that I knew it would be 
helpful). I am concerned about getting clots 
because I know it is not extremely uncommond 
with birth control. Thanks for doing this research. 
I hope it will help many women to know the risks 
and be wise in their decisions. 
 Wed, 2/11/09 3:27 PM  
  67. Changed pills many different times due to not 
good fit for body/acclimation. Decided to quit 
taking as had gone through so many with side 
effects(non-serious). 
 Wed, 2/11/09 3:16 PM  
  68. I stopped taking BC pills in August of 2004 b/c I 
felt that my hormones/emotions were out of 
control. I had been taking orthocyclin at the time 
and had been on that pill for a few years. I recently 
started taking them again (2009) after having a 
baby b/c I wanted to use a different form of BC. 
I'm on a different RX, so I'll see how this goes. 
 Wed, 2/11/09 3:14 PM  
  69. I recognize the importance of this study, however, 
most of the questions are in reference to when I 
first was put on birth control. Since that time (16 




years old), I have moved and switched doctors on 
several occasions and they all handle the process 
differently. To be honest, I don't necessarily 
remember if I received information when I first 
got prescribed - that was over 14 years ago. 
  70. i had to come off birth controls due to depressive 
symptoms. they symptoms lifted immediately after 
30 days of coming off b/c pill. 
 Wed, 2/11/09 2:58 PM  
  71. I HATED IT! BC makes me crazy. I have a copper 
IUD that suites me well and does not alter my 
emotional state whereas taking hormones does. 
And, for some reason, I'm more comfortable with 
"blocking" or combating sperm with scary copper 
rather than messing with the hormone balance of 
my body and tricking it into believe it's perpetually 
pregnant. 
 Wed, 2/11/09 2:43 PM  
  72. i started gaining weight when i started the pill. 
therefore i quit taking it and decided to endure 
cramps. 
 Wed, 2/11/09 2:28 PM  
  73. I liked them, especially Seasonale, which reduces 
menstrual periods to four per year. 
 Wed, 2/11/09 2:27 PM  
  74. I took the pill for twenty or so years. I stopped 
taking them the minute I was married in hopes of 
starting a family. I was unable to become 
pregnant. I ran out of eggs. I personally believe 
girls/women should NOT stay on BC pills for 
extended periods of time, I believe the pill is the 
reason so many people in the 40-50 age range 
today are unable to have children. I think back in 
the 70's we did not have enough information, and 
now we are paying the price by being infertile. 
 Wed, 2/11/09 2:25 PM  
  75. I was not aware, in 2003, when I loaded up on 
vitamins and herbal supplements that they could 
change the effectiveness of the pill...hence, my 
son! The last time I did purchase the pill it did 
have a sticker referring to that but I am not sure 
how aware ladies are of that issue. 
 Wed, 2/11/09 2:20 PM  
  76. I experienced bilateral pulmonary embolisms 
when I was taking birth control pills. It turned out 
that I had factor V Leiden (homozygous), but my 
family was unaware of our genetic condition until 
I had my clots. I can't remember my doctor ever 
discussing blood clot risks with me when 




prescribing BCPs. My grandfather had had a 
stroke, but I don't recall discussing that. I 
originally took Ortho Tri-cyclen, but the doctor (at 
the student health clinic) switched me to Mircette 
to help with migraines. It turns out this is one of 
the types of BCPs that causes the greatest risk for 
clots. 
  77. Discontinued use of pills in favor of other birth 
control methods, including patch and shot. 
 Wed, 2/11/09 1:59 PM  
  78. My experience with trying to take depo has been 
frustrating because some health care providers are 
against it (because it ceases menstruation), and it 
is not as well covered by insurance. Also, some 
doctors are not diligent about making sure patients 
stay on schedule, or following up with options 
when a shot is missed. I feel like there is a huge 
amount of stigma associated with birth control and 
which type you take, and how you are perceived 
by your health care provider, friends and others 
based on your choice. I feel like there are several 
facts and myths about birth control that the public 
needs to be educated on. For example, there is a 
perception out there that it is unhealthy to miss 
your period due to medication like depo. 
 Wed, 2/11/09 1:59 PM  
  79. they made me a moody bitch!  Wed, 2/11/09 1:40 PM  
  80. It's hard for me to remember everything that 
happened when I was 19, but I do remember that, 
independent of telling me that I was fat, my doctor 
was good and left me feeling informed. I also 
remember being on the look out for blood clot 
symptoms after starting the pill. But I was not 
tested for any pre-existing conditions to make sure 
it was safe for me. 
 Wed, 2/11/09 12:53 PM 
  81. i stopped taking them in 2008. I did find that 
taking them made my period lighter and more 
managable. I have not felt that much different 
being off it the pills. 
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